Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells
Identifieur interne : 000434 ( Pmc/Corpus ); précédent : 000433; suivant : 000435Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells
Auteurs : Seog-Young Kim ; Dae-Hee Lee ; Xinxin Song ; David L. Bartlett ; Yong Tae Kwon ; Yong J. LeeSource :
- Apoptosis [ 1360-8185 ] ; 2014.
Abstract
In this study, we attempted to develop a multimodality approach using chemotherapeutic agent mitomycin C, biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L), and mild hyperthermia to treat colon cancer. For this study, human colon cancer LS174T, LS180, HCT116 and CX-1 cells were infected with secretory TRAIL-armed adenovirus (Ad.TRAIL) and treated with chemotherapeutic agent mitomycin C and hyperthermia. The combinatorial treatment caused a synergistic induction of apoptosis which was mediated through an increase in caspase activation. The combinational treatment promoted the JNK-Bcl-xL-Bak pathway which transmitted the synergistic effect through the mitochondria-dependent apoptotic pathway. JNK signaling led to Bcl-xL phosphorylation at serine 62, dissociation of Bak from Bcl-xL, oligomerization of Bak, alteration of mitochondrial membrane potential, and subsequent cytochrome
Url:
DOI: 10.1007/s10495-014-1028-6
PubMed: 25156145
PubMed Central: 4196052
Links to Exploration step
PMC:4196052Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells</title><author><name sortKey="Kim, Seog Young" sort="Kim, Seog Young" uniqKey="Kim S" first="Seog-Young" last="Kim">Seog-Young Kim</name><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author><author><name sortKey="Lee, Dae Hee" sort="Lee, Dae Hee" uniqKey="Lee D" first="Dae-Hee" last="Lee">Dae-Hee Lee</name><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author><author><name sortKey="Song, Xinxin" sort="Song, Xinxin" uniqKey="Song X" first="Xinxin" last="Song">Xinxin Song</name><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author><author><name sortKey="Bartlett, David L" sort="Bartlett, David L" uniqKey="Bartlett D" first="David L." last="Bartlett">David L. Bartlett</name><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author><author><name sortKey="Kwon, Yong Tae" sort="Kwon, Yong Tae" uniqKey="Kwon Y" first="Yong Tae" last="Kwon">Yong Tae Kwon</name><affiliation><nlm:aff id="Aff3">Protein Metabolism Medical Research Center and Department of Biomedical Science, College of Medicine, Seoul National University, Seoul, 110-799 Korea</nlm:aff></affiliation></author><author><name sortKey="Lee, Yong J" sort="Lee, Yong J" uniqKey="Lee Y" first="Yong J." last="Lee">Yong J. Lee</name><affiliation><nlm:aff id="Aff2">Department of Pharmacology & Chemical Biology, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213, USA</nlm:aff></affiliation><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25156145</idno><idno type="pmc">4196052</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196052</idno><idno type="RBID">PMC:4196052</idno><idno type="doi">10.1007/s10495-014-1028-6</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000434</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000434</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells</title><author><name sortKey="Kim, Seog Young" sort="Kim, Seog Young" uniqKey="Kim S" first="Seog-Young" last="Kim">Seog-Young Kim</name><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author><author><name sortKey="Lee, Dae Hee" sort="Lee, Dae Hee" uniqKey="Lee D" first="Dae-Hee" last="Lee">Dae-Hee Lee</name><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author><author><name sortKey="Song, Xinxin" sort="Song, Xinxin" uniqKey="Song X" first="Xinxin" last="Song">Xinxin Song</name><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author><author><name sortKey="Bartlett, David L" sort="Bartlett, David L" uniqKey="Bartlett D" first="David L." last="Bartlett">David L. Bartlett</name><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author><author><name sortKey="Kwon, Yong Tae" sort="Kwon, Yong Tae" uniqKey="Kwon Y" first="Yong Tae" last="Kwon">Yong Tae Kwon</name><affiliation><nlm:aff id="Aff3">Protein Metabolism Medical Research Center and Department of Biomedical Science, College of Medicine, Seoul National University, Seoul, 110-799 Korea</nlm:aff></affiliation></author><author><name sortKey="Lee, Yong J" sort="Lee, Yong J" uniqKey="Lee Y" first="Yong J." last="Lee">Yong J. Lee</name><affiliation><nlm:aff id="Aff2">Department of Pharmacology & Chemical Biology, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213, USA</nlm:aff></affiliation><affiliation><nlm:aff id="Aff1">Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</nlm:aff></affiliation></author></analytic><series><title level="j">Apoptosis</title><idno type="ISSN">1360-8185</idno><idno type="eISSN">1573-675X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>In this study, we attempted to develop a multimodality approach using chemotherapeutic agent mitomycin C, biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L), and mild hyperthermia to treat colon cancer. For this study, human colon cancer LS174T, LS180, HCT116 and CX-1 cells were infected with secretory TRAIL-armed adenovirus (Ad.TRAIL) and treated with chemotherapeutic agent mitomycin C and hyperthermia. The combinatorial treatment caused a synergistic induction of apoptosis which was mediated through an increase in caspase activation. The combinational treatment promoted the JNK-Bcl-xL-Bak pathway which transmitted the synergistic effect through the mitochondria-dependent apoptotic pathway. JNK signaling led to Bcl-xL phosphorylation at serine 62, dissociation of Bak from Bcl-xL, oligomerization of Bak, alteration of mitochondrial membrane potential, and subsequent cytochrome <italic>c</italic> release. Overexpression of dominant-negative mutant of Bcl-xL (S62A), but not dominant-positive mutant of Bcl-xL (S62D), suppressed the synergistic death effect. Interestingly, Beclin-1 was dissociated from Bcl-xL and overexpression of dominant-negative mutant of Bcl-xL (S62A), but not dominant-positive mutant of Bcl-xL (S62D), suppressed dissociation of Beclin-1 from Bcl-xL. A combinatorial treatment of mitomycin C, Ad.TRAIL and hyperthermia induced Beclin-1 cleavage, but the Beclin-1 cleavage was abolished in Beclin-1 double mutant (D133A/D146A) knock-in HCT116 cells, suppressing the apoptosis induced by the combination therapy. We believe that this study supports the application of the multimodality approach to colon cancer therapy.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Chua, Tc" uniqKey="Chua T">TC Chua</name></author><author><name sortKey="Esquivel, J" uniqKey="Esquivel J">J Esquivel</name></author><author><name sortKey="Pelz, Jo" uniqKey="Pelz J">JO Pelz</name></author><author><name sortKey="Morris, Dl" uniqKey="Morris D">DL Morris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saltz, Lb" uniqKey="Saltz L">LB Saltz</name></author><author><name sortKey="Cox, Jv" uniqKey="Cox J">JV Cox</name></author><author><name sortKey="Blanke, C" uniqKey="Blanke C">C Blanke</name></author><author><name sortKey="Rosen, Ls" uniqKey="Rosen L">LS Rosen</name></author><author><name sortKey="Fehrenbacher, L" uniqKey="Fehrenbacher L">L Fehrenbacher</name></author><author><name sortKey="Moore, Mj" uniqKey="Moore M">MJ Moore</name></author><author><name sortKey="Maroun, Ja" uniqKey="Maroun J">JA Maroun</name></author><author><name sortKey="Ackland, Sp" uniqKey="Ackland S">SP Ackland</name></author><author><name sortKey="Locker, Pk" uniqKey="Locker P">PK Locker</name></author><author><name sortKey="Pirotta, N" uniqKey="Pirotta N">N Pirotta</name></author><author><name sortKey="Elfring, Gl" uniqKey="Elfring G">GL Elfring</name></author><author><name sortKey="Miller, Ll" uniqKey="Miller L">LL Miller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hurwitz, H" uniqKey="Hurwitz H">H Hurwitz</name></author><author><name sortKey="Fehrenbacher, L" uniqKey="Fehrenbacher L">L Fehrenbacher</name></author><author><name sortKey="Novotny, W" uniqKey="Novotny W">W Novotny</name></author><author><name sortKey="Cartwright, T" uniqKey="Cartwright T">T Cartwright</name></author><author><name sortKey="Hainsworth, J" uniqKey="Hainsworth J">J Hainsworth</name></author><author><name sortKey="Heim, W" uniqKey="Heim W">W Heim</name></author><author><name sortKey="Berlin, J" uniqKey="Berlin J">J Berlin</name></author><author><name sortKey="Baron, A" uniqKey="Baron A">A Baron</name></author><author><name sortKey="Griffing, S" uniqKey="Griffing S">S Griffing</name></author><author><name sortKey="Holmgren, E" uniqKey="Holmgren E">E Holmgren</name></author><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N Ferrara</name></author><author><name sortKey="Fyfe, G" uniqKey="Fyfe G">G Fyfe</name></author><author><name sortKey="Rogers, B" uniqKey="Rogers B">B Rogers</name></author><author><name sortKey="Ross, R" uniqKey="Ross R">R Ross</name></author><author><name sortKey="Kabbinavar, F" uniqKey="Kabbinavar F">F Kabbinavar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Colucci, G" uniqKey="Colucci G">G Colucci</name></author><author><name sortKey="Gebbia, V" uniqKey="Gebbia V">V Gebbia</name></author><author><name sortKey="Paoletti, G" uniqKey="Paoletti G">G Paoletti</name></author><author><name sortKey="Giuliani, F" uniqKey="Giuliani F">F Giuliani</name></author><author><name sortKey="Caruso, M" uniqKey="Caruso M">M Caruso</name></author><author><name sortKey="Gebbia, N" uniqKey="Gebbia N">N Gebbia</name></author><author><name sortKey="Carteni, G" uniqKey="Carteni G">G Cartenì</name></author><author><name sortKey="Agostara, B" uniqKey="Agostara B">B Agostara</name></author><author><name sortKey="Pezzella, G" uniqKey="Pezzella G">G Pezzella</name></author><author><name sortKey="Manzione, L" uniqKey="Manzione L">L Manzione</name></author><author><name sortKey="Borsellino, N" uniqKey="Borsellino N">N Borsellino</name></author><author><name sortKey="Misino, A" uniqKey="Misino A">A Misino</name></author><author><name sortKey="Romito, S" uniqKey="Romito S">S Romito</name></author><author><name sortKey="Durini, E" uniqKey="Durini E">E Durini</name></author><author><name sortKey="Cordio, S" uniqKey="Cordio S">S Cordio</name></author><author><name sortKey="Di Seri, M" uniqKey="Di Seri M">M Di Seri</name></author><author><name sortKey="Lopez, M" uniqKey="Lopez M">M Lopez</name></author><author><name sortKey="Maiello, E" uniqKey="Maiello E">E Maiello</name></author><author><name sortKey="Montemurro, S" uniqKey="Montemurro S">S Montemurro</name></author><author><name sortKey="Cramarossa, A" uniqKey="Cramarossa A">A Cramarossa</name></author><author><name sortKey="Lorusso, V" uniqKey="Lorusso V">V Lorusso</name></author><author><name sortKey="Di Bisceglie, M" uniqKey="Di Bisceglie M">M Di Bisceglie</name></author><author><name sortKey="Chiarenza, M" uniqKey="Chiarenza M">M Chiarenza</name></author><author><name sortKey="Valerio, Mr" uniqKey="Valerio M">MR Valerio</name></author><author><name sortKey="Guida, T" uniqKey="Guida T">T Guida</name></author><author><name sortKey="Leonardi, V" uniqKey="Leonardi V">V Leonardi</name></author><author><name sortKey="Pisconti, S" uniqKey="Pisconti S">S Pisconti</name></author><author><name sortKey="Rosati, G" uniqKey="Rosati G">G Rosati</name></author><author><name sortKey="Carrozza, F" uniqKey="Carrozza F">F Carrozza</name></author><author><name sortKey="Nettis, G" uniqKey="Nettis G">G Nettis</name></author><author><name sortKey="Valdesi, M" uniqKey="Valdesi M">M Valdesi</name></author><author><name sortKey="Filippelli, G" uniqKey="Filippelli G">G Filippelli</name></author><author><name sortKey="Fortunato, S" uniqKey="Fortunato S">S Fortunato</name></author><author><name sortKey="Mancarella, S" uniqKey="Mancarella S">S Mancarella</name></author><author><name sortKey="Brunetti, C" uniqKey="Brunetti C">C Brunetti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cassidy, J" uniqKey="Cassidy J">J Cassidy</name></author><author><name sortKey="Clarke, S" uniqKey="Clarke S">S Clarke</name></author><author><name sortKey="Diaz Rubio, E" uniqKey="Diaz Rubio E">E Díaz-Rubio</name></author><author><name sortKey="Scheithauer, W" uniqKey="Scheithauer W">W Scheithauer</name></author><author><name sortKey="Figer, A" uniqKey="Figer A">A Figer</name></author><author><name sortKey="Wong, R" uniqKey="Wong R">R Wong</name></author><author><name sortKey="Koski, S" uniqKey="Koski S">S Koski</name></author><author><name sortKey="Lichinitser, M" uniqKey="Lichinitser M">M Lichinitser</name></author><author><name sortKey="Yang, Ts" uniqKey="Yang T">TS Yang</name></author><author><name sortKey="Rivera, F" uniqKey="Rivera F">F Rivera</name></author><author><name sortKey="Couture, F" uniqKey="Couture F">F Couture</name></author><author><name sortKey="Sirzen, F" uniqKey="Sirzen F">F Sirzén</name></author><author><name sortKey="Saltz, L" uniqKey="Saltz L">L Saltz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Porschen, R" uniqKey="Porschen R">R Porschen</name></author><author><name sortKey="Arkenau, Ht" uniqKey="Arkenau H">HT Arkenau</name></author><author><name sortKey="Kubicka, S" uniqKey="Kubicka S">S Kubicka</name></author><author><name sortKey="Greil, R" uniqKey="Greil R">R Greil</name></author><author><name sortKey="Seufferlein, T" uniqKey="Seufferlein T">T Seufferlein</name></author><author><name sortKey="Freier, W" uniqKey="Freier W">W Freier</name></author><author><name sortKey="Kretzschmar, A" uniqKey="Kretzschmar A">A Kretzschmar</name></author><author><name sortKey="Graeven, U" uniqKey="Graeven U">U Graeven</name></author><author><name sortKey="Grothey, A" uniqKey="Grothey A">A Grothey</name></author><author><name sortKey="Hinke, A" uniqKey="Hinke A">A Hinke</name></author><author><name sortKey="Schmiegel, W" uniqKey="Schmiegel W">W Schmiegel</name></author><author><name sortKey="Schmoll, Hj" uniqKey="Schmoll H">HJ Schmoll</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saltz, Lb" uniqKey="Saltz L">LB Saltz</name></author><author><name sortKey="Clarke, S" uniqKey="Clarke S">S Clarke</name></author><author><name sortKey="Diaz Rubio, E" uniqKey="Diaz Rubio E">E Díaz-Rubio</name></author><author><name sortKey="Scheithauer, W" uniqKey="Scheithauer W">W Scheithauer</name></author><author><name sortKey="Figer, A" uniqKey="Figer A">A Figer</name></author><author><name sortKey="Wong, R" uniqKey="Wong R">R Wong</name></author><author><name sortKey="Koski, S" uniqKey="Koski S">S Koski</name></author><author><name sortKey="Lichinitser, M" uniqKey="Lichinitser M">M Lichinitser</name></author><author><name sortKey="Yang, Ts" uniqKey="Yang T">TS Yang</name></author><author><name sortKey="Rivera, F" uniqKey="Rivera F">F Rivera</name></author><author><name sortKey="Couture, F" uniqKey="Couture F">F Couture</name></author><author><name sortKey="Sirzen, F" uniqKey="Sirzen F">F Sirzén</name></author><author><name sortKey="Cassidy, J" uniqKey="Cassidy J">J Cassidy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falcone, A" uniqKey="Falcone A">A Falcone</name></author><author><name sortKey="Ricci, S" uniqKey="Ricci S">S Ricci</name></author><author><name sortKey="Brunetti, I" uniqKey="Brunetti I">I Brunetti</name></author><author><name sortKey="Pfanner, E" uniqKey="Pfanner E">E Pfanner</name></author><author><name sortKey="Allegrini, G" uniqKey="Allegrini G">G Allegrini</name></author><author><name sortKey="Barbara, C" uniqKey="Barbara C">C Barbara</name></author><author><name sortKey="Crin, L" uniqKey="Crin L">L Crinò</name></author><author><name sortKey="Benedetti, G" uniqKey="Benedetti G">G Benedetti</name></author><author><name sortKey="Evangelista, W" uniqKey="Evangelista W">W Evangelista</name></author><author><name sortKey="Fanchini, L" uniqKey="Fanchini L">L Fanchini</name></author><author><name sortKey="Cortesi, E" uniqKey="Cortesi E">E Cortesi</name></author><author><name sortKey="Picone, V" uniqKey="Picone V">V Picone</name></author><author><name sortKey="Vitello, S" uniqKey="Vitello S">S Vitello</name></author><author><name sortKey="Chiara, S" uniqKey="Chiara S">S Chiara</name></author><author><name sortKey="Granetto, C" uniqKey="Granetto C">C Granetto</name></author><author><name sortKey="Porcile, G" uniqKey="Porcile G">G Porcile</name></author><author><name sortKey="Fioretto, L" uniqKey="Fioretto L">L Fioretto</name></author><author><name sortKey="Orlandini, C" uniqKey="Orlandini C">C Orlandini</name></author><author><name sortKey="Andreuccetti, M" uniqKey="Andreuccetti M">M Andreuccetti</name></author><author><name sortKey="Masi, G" uniqKey="Masi G">G Masi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeh, Hj" uniqKey="Zeh H">HJ Zeh</name></author><author><name sortKey="Brown, Ck" uniqKey="Brown C">CK Brown</name></author><author><name sortKey="Holtzman, Mp" uniqKey="Holtzman M">MP Holtzman</name></author><author><name sortKey="Egorin, Mj" uniqKey="Egorin M">MJ Egorin</name></author><author><name sortKey="Holleran, Jl" uniqKey="Holleran J">JL Holleran</name></author><author><name sortKey="Potter, Dm" uniqKey="Potter D">DM Potter</name></author><author><name sortKey="Bartlett, Dl" uniqKey="Bartlett D">DL Bartlett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ceelen, Wp" uniqKey="Ceelen W">WP Ceelen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Siddik, Zh" uniqKey="Siddik Z">ZH Siddik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chong, G" uniqKey="Chong G">G Chong</name></author><author><name sortKey="Dickson, Jl" uniqKey="Dickson J">JL Dickson</name></author><author><name sortKey="Cunningham, D" uniqKey="Cunningham D">D Cunningham</name></author><author><name sortKey="Norman, Ar" uniqKey="Norman A">AR Norman</name></author><author><name sortKey="Rao, S" uniqKey="Rao S">S Rao</name></author><author><name sortKey="Hill, Me" uniqKey="Hill M">ME Hill</name></author><author><name sortKey="Price, Tj" uniqKey="Price T">TJ Price</name></author><author><name sortKey="Oates, J" uniqKey="Oates J">J Oates</name></author><author><name sortKey="Tebbutt, N" uniqKey="Tebbutt N">N Tebbutt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tanabe, M" uniqKey="Tanabe M">M Tanabe</name></author><author><name sortKey="Ito, Y" uniqKey="Ito Y">Y Ito</name></author><author><name sortKey="Tokudome, N" uniqKey="Tokudome N">N Tokudome</name></author><author><name sortKey="Sugihara, T" uniqKey="Sugihara T">T Sugihara</name></author><author><name sortKey="Miura, H" uniqKey="Miura H">H Miura</name></author><author><name sortKey="Takahashi, S" uniqKey="Takahashi S">S Takahashi</name></author><author><name sortKey="Seto, Y" uniqKey="Seto Y">Y Seto</name></author><author><name sortKey="Iwase, T" uniqKey="Iwase T">T Iwase</name></author><author><name sortKey="Hatake, K" uniqKey="Hatake K">K Hatake</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berghmans, T" uniqKey="Berghmans T">T Berghmans</name></author><author><name sortKey="Gourcerol, D" uniqKey="Gourcerol D">D Gourcerol</name></author><author><name sortKey="Lafitte, Jj" uniqKey="Lafitte J">JJ Lafitte</name></author><author><name sortKey="Kotsori, K" uniqKey="Kotsori K">K Kotsori</name></author><author><name sortKey="Paesmans, M" uniqKey="Paesmans M">M Paesmans</name></author><author><name sortKey="Scherpereel, A" uniqKey="Scherpereel A">A Scherpereel</name></author><author><name sortKey="Leclercq, N" uniqKey="Leclercq N">N Leclercq</name></author><author><name sortKey="Sculier, Jp" uniqKey="Sculier J">JP Sculier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Horvath, A" uniqKey="Horvath A">A Horvath</name></author><author><name sortKey="Mostafid, H" uniqKey="Mostafid H">H Mostafid</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iyer, Vn" uniqKey="Iyer V">VN Iyer</name></author><author><name sortKey="Szybalski, W" uniqKey="Szybalski W">W Szybalski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iyer, Vn" uniqKey="Iyer V">VN Iyer</name></author><author><name sortKey="Szybalski, W" uniqKey="Szybalski W">W Szybalski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, Sk" uniqKey="Carter S">SK Carter</name></author><author><name sortKey="Comis, Rl" uniqKey="Comis R">RL Comis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Whittington, Rm" uniqKey="Whittington R">RM Whittington</name></author><author><name sortKey="Close, Hp" uniqKey="Close H">HP Close</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, Sk" uniqKey="Carter S">SK Carter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moore, Ge" uniqKey="Moore G">GE Moore</name></author><author><name sortKey="Bross, Id" uniqKey="Bross I">ID Bross</name></author><author><name sortKey="Ausmans, R" uniqKey="Ausmans R">R Ausmans</name></author><author><name sortKey="Nadler, S" uniqKey="Nadler S">S Nadler</name></author><author><name sortKey="Jones, R" uniqKey="Jones R">R Jones</name></author><author><name sortKey="Slack, N" uniqKey="Slack N">N Slack</name></author><author><name sortKey="Rimm, Aa" uniqKey="Rimm A">AA Rimm</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kano, Y" uniqKey="Kano Y">Y Kano</name></author><author><name sortKey="Suzuki, K" uniqKey="Suzuki K">K Suzuki</name></author><author><name sortKey="Akutsu, M" uniqKey="Akutsu M">M Akutsu</name></author><author><name sortKey="Suda, K" uniqKey="Suda K">K Suda</name></author><author><name sortKey="Inoue, Y" uniqKey="Inoue Y">Y Inoue</name></author><author><name sortKey="Yoshida, M" uniqKey="Yoshida M">M Yoshida</name></author><author><name sortKey="Sakamoto, S" uniqKey="Sakamoto S">S Sakamoto</name></author><author><name sortKey="Miura, Y" uniqKey="Miura Y">Y Miura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sawada, N" uniqKey="Sawada N">N Sawada</name></author><author><name sortKey="Ishikawa, T" uniqKey="Ishikawa T">T Ishikawa</name></author><author><name sortKey="Fukase, Y" uniqKey="Fukase Y">Y Fukase</name></author><author><name sortKey="Nishida, M" uniqKey="Nishida M">M Nishida</name></author><author><name sortKey="Yoshikubo, T" uniqKey="Yoshikubo T">T Yoshikubo</name></author><author><name sortKey="Ishitsuka, H" uniqKey="Ishitsuka H">H Ishitsuka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Franchi, F" uniqKey="Franchi F">F Franchi</name></author><author><name sortKey="Barone, C" uniqKey="Barone C">C Barone</name></author><author><name sortKey="Seminara, P" uniqKey="Seminara P">P Seminara</name></author><author><name sortKey="Codacci Pisanelli, G" uniqKey="Codacci Pisanelli G">G Codacci-Pisanelli</name></author><author><name sortKey="Codacci Pisanelli, M" uniqKey="Codacci Pisanelli M">M Codacci-Pisanelli</name></author><author><name sortKey="Ferri, Gm" uniqKey="Ferri G">GM Ferri</name></author><author><name sortKey="Garufi, C" uniqKey="Garufi C">C Garufi</name></author><author><name sortKey="Grieco, A" uniqKey="Grieco A">A Grieco</name></author><author><name sortKey="Pagani, V" uniqKey="Pagani V">V Pagani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pan, G" uniqKey="Pan G">G Pan</name></author><author><name sortKey="O Ourke, K" uniqKey="O Ourke K">K O’Rourke</name></author><author><name sortKey="Chinnaiyan, Am" uniqKey="Chinnaiyan A">AM Chinnaiyan</name></author><author><name sortKey="Gentz, R" uniqKey="Gentz R">R Gentz</name></author><author><name sortKey="Ebner, R" uniqKey="Ebner R">R Ebner</name></author><author><name sortKey="Ni, J" uniqKey="Ni J">J Ni</name></author><author><name sortKey="Dixit, Vm" uniqKey="Dixit V">VM Dixit</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pan, G" uniqKey="Pan G">G Pan</name></author><author><name sortKey="Ni, J" uniqKey="Ni J">J Ni</name></author><author><name sortKey="Wei, Yf" uniqKey="Wei Y">YF Wei</name></author><author><name sortKey="Yu, G" uniqKey="Yu G">G Yu</name></author><author><name sortKey="Gentz, R" uniqKey="Gentz R">R Gentz</name></author><author><name sortKey="Dixit, Vm" uniqKey="Dixit V">VM Dixit</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schneider, P" uniqKey="Schneider P">P Schneider</name></author><author><name sortKey="Thome, M" uniqKey="Thome M">M Thome</name></author><author><name sortKey="Burns, K" uniqKey="Burns K">K Burns</name></author><author><name sortKey="Bodmer, Jl" uniqKey="Bodmer J">JL Bodmer</name></author><author><name sortKey="Hofmann, K" uniqKey="Hofmann K">K Hofmann</name></author><author><name sortKey="Kataoka, T" uniqKey="Kataoka T">T Kataoka</name></author><author><name sortKey="Holler, N" uniqKey="Holler N">N Holler</name></author><author><name sortKey="Tschopp, J" uniqKey="Tschopp J">J Tschopp</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaudhary, Pm" uniqKey="Chaudhary P">PM Chaudhary</name></author><author><name sortKey="Eby, M" uniqKey="Eby M">M Eby</name></author><author><name sortKey="Jasmin, A" uniqKey="Jasmin A">A Jasmin</name></author><author><name sortKey="Bookwalter, A" uniqKey="Bookwalter A">A Bookwalter</name></author><author><name sortKey="Murray, J" uniqKey="Murray J">J Murray</name></author><author><name sortKey="Hood, L" uniqKey="Hood L">L Hood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walczak, H" uniqKey="Walczak H">H Walczak</name></author><author><name sortKey="Degli Esposti, Ma" uniqKey="Degli Esposti M">MA Degli-Esposti</name></author><author><name sortKey="Johnson, Rs" uniqKey="Johnson R">RS Johnson</name></author><author><name sortKey="Smolak, Pj" uniqKey="Smolak P">PJ Smolak</name></author><author><name sortKey="Waugh, Jy" uniqKey="Waugh J">JY Waugh</name></author><author><name sortKey="Boiani, N" uniqKey="Boiani N">N Boiani</name></author><author><name sortKey="Timour, Ms" uniqKey="Timour M">MS Timour</name></author><author><name sortKey="Gerhart, Mj" uniqKey="Gerhart M">MJ Gerhart</name></author><author><name sortKey="Schooley, Ka" uniqKey="Schooley K">KA Schooley</name></author><author><name sortKey="Smith, Ca" uniqKey="Smith C">CA Smith</name></author><author><name sortKey="Goodwin, Rg" uniqKey="Goodwin R">RG Goodwin</name></author><author><name sortKey="Rauch, Ct" uniqKey="Rauch C">CT Rauch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, Gs" uniqKey="Wu G">GS Wu</name></author><author><name sortKey="Burns, Tf" uniqKey="Burns T">TF Burns</name></author><author><name sortKey="Mcdonald, Er" uniqKey="Mcdonald E">ER McDonald</name></author><author><name sortKey="Jiang, W" uniqKey="Jiang W">W Jiang</name></author><author><name sortKey="Meng, R" uniqKey="Meng R">R Meng</name></author><author><name sortKey="Krantz, Id" uniqKey="Krantz I">ID Krantz</name></author><author><name sortKey="Kao, G" uniqKey="Kao G">G Kao</name></author><author><name sortKey="Gan, Dd" uniqKey="Gan D">DD Gan</name></author><author><name sortKey="Zhou, Jy" uniqKey="Zhou J">JY Zhou</name></author><author><name sortKey="Muschel, R" uniqKey="Muschel R">R Muschel</name></author><author><name sortKey="Hamilton, Sr" uniqKey="Hamilton S">SR Hamilton</name></author><author><name sortKey="Spinner, Nb" uniqKey="Spinner N">NB Spinner</name></author><author><name sortKey="Markowitz, S" uniqKey="Markowitz S">S Markowitz</name></author><author><name sortKey="Wu, G" uniqKey="Wu G">G Wu</name></author><author><name sortKey="El Deiry, Ws" uniqKey="El Deiry W">WS el-Deiry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wiley, Sr" uniqKey="Wiley S">SR Wiley</name></author><author><name sortKey="Schooley, K" uniqKey="Schooley K">K Schooley</name></author><author><name sortKey="Smolak, Pj" uniqKey="Smolak P">PJ Smolak</name></author><author><name sortKey="Din, Ws" uniqKey="Din W">WS Din</name></author><author><name sortKey="Huang, Cp" uniqKey="Huang C">CP Huang</name></author><author><name sortKey="Nicholl, Jk" uniqKey="Nicholl J">JK Nicholl</name></author><author><name sortKey="Sutherland, Gr" uniqKey="Sutherland G">GR Sutherland</name></author><author><name sortKey="Smith, Td" uniqKey="Smith T">TD Smith</name></author><author><name sortKey="Rauch, C" uniqKey="Rauch C">C Rauch</name></author><author><name sortKey="Smith, Ca" uniqKey="Smith C">CA Smith</name></author><author><name sortKey="Goodwin, Rg" uniqKey="Goodwin R">RG Goodwin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Griffith, Ts" uniqKey="Griffith T">TS Griffith</name></author><author><name sortKey="Lynch, Dh" uniqKey="Lynch D">DH Lynch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lacour, S" uniqKey="Lacour S">S Lacour</name></author><author><name sortKey="Hammann, A" uniqKey="Hammann A">A Hammann</name></author><author><name sortKey="Wotawa, A" uniqKey="Wotawa A">A Wotawa</name></author><author><name sortKey="Corcos, L" uniqKey="Corcos L">L Corcos</name></author><author><name sortKey="Solary, E" uniqKey="Solary E">E Solary</name></author><author><name sortKey="Dimanche Boitrel, Mt" uniqKey="Dimanche Boitrel M">MT Dimanche-Boitrel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keane, Mm" uniqKey="Keane M">MM Keane</name></author><author><name sortKey="Ettenberg, Sa" uniqKey="Ettenberg S">SA Ettenberg</name></author><author><name sortKey="Nau, Mm" uniqKey="Nau M">MM Nau</name></author><author><name sortKey="Russell, Ek" uniqKey="Russell E">EK Russell</name></author><author><name sortKey="Lipkowitz, S" uniqKey="Lipkowitz S">S Lipkowitz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nagane, M" uniqKey="Nagane M">M Nagane</name></author><author><name sortKey="Pan, G" uniqKey="Pan G">G Pan</name></author><author><name sortKey="Weddle, Jj" uniqKey="Weddle J">JJ Weddle</name></author><author><name sortKey="Dixit, Vm" uniqKey="Dixit V">VM Dixit</name></author><author><name sortKey="Cavenee, Wk" uniqKey="Cavenee W">WK Cavenee</name></author><author><name sortKey="Huang, Hj" uniqKey="Huang H">HJ Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gibson, Sb" uniqKey="Gibson S">SB Gibson</name></author><author><name sortKey="Oyer, R" uniqKey="Oyer R">R Oyer</name></author><author><name sortKey="Spalding, Ac" uniqKey="Spalding A">AC Spalding</name></author><author><name sortKey="Anderson, Sm" uniqKey="Anderson S">SM Anderson</name></author><author><name sortKey="Johnson, Gl" uniqKey="Johnson G">GL Johnson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singh, Tr" uniqKey="Singh T">TR Singh</name></author><author><name sortKey="Shankar, S" uniqKey="Shankar S">S Shankar</name></author><author><name sortKey="Chen, X" uniqKey="Chen X">X Chen</name></author><author><name sortKey="Asim, M" uniqKey="Asim M">M Asim</name></author><author><name sortKey="Srivastava, Rk" uniqKey="Srivastava R">RK Srivastava</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Asakuma, J" uniqKey="Asakuma J">J Asakuma</name></author><author><name sortKey="Sumitomo, M" uniqKey="Sumitomo M">M Sumitomo</name></author><author><name sortKey="Asano, T" uniqKey="Asano T">T Asano</name></author><author><name sortKey="Hayakawa, M" uniqKey="Hayakawa M">M Hayakawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stuckey, Dw" uniqKey="Stuckey D">DW Stuckey</name></author><author><name sortKey="Shah, K" uniqKey="Shah K">K Shah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yoo, J" uniqKey="Yoo J">J Yoo</name></author><author><name sortKey="Kim, Hr" uniqKey="Kim H">HR Kim</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yoo, J" uniqKey="Yoo J">J Yoo</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, X" uniqKey="Song X">X Song</name></author><author><name sortKey="Kim, Hc" uniqKey="Kim H">HC Kim</name></author><author><name sortKey="Kim, Sy" uniqKey="Kim S">SY Kim</name></author><author><name sortKey="Basse, P" uniqKey="Basse P">P Basse</name></author><author><name sortKey="Park, Bh" uniqKey="Park B">BH Park</name></author><author><name sortKey="Lee, Bc" uniqKey="Lee B">BC Lee</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, X" uniqKey="Song X">X Song</name></author><author><name sortKey="Kim, Sy" uniqKey="Kim S">SY Kim</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dewey, Wc" uniqKey="Dewey W">WC Dewey</name></author><author><name sortKey="Sapareto, Sa" uniqKey="Sapareto S">SA Sapareto</name></author><author><name sortKey="Betten, Da" uniqKey="Betten D">DA Betten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holahan, Ev" uniqKey="Holahan E">EV Holahan</name></author><author><name sortKey="Highfield, Dp" uniqKey="Highfield D">DP Highfield</name></author><author><name sortKey="Holahan, Pk" uniqKey="Holahan P">PK Holahan</name></author><author><name sortKey="Dewey, Wc" uniqKey="Dewey W">WC Dewey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kampinga, Hh" uniqKey="Kampinga H">HH Kampinga</name></author><author><name sortKey="Dikomey, E" uniqKey="Dikomey E">E Dikomey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haas, Gp" uniqKey="Haas G">GP Haas</name></author><author><name sortKey="Klugo, Rc" uniqKey="Klugo R">RC Klugo</name></author><author><name sortKey="Hetzel, Fw" uniqKey="Hetzel F">FW Hetzel</name></author><author><name sortKey="Barton, Ee" uniqKey="Barton E">EE Barton</name></author><author><name sortKey="Cerny, Jc" uniqKey="Cerny J">JC Cerny</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Herman, Ts" uniqKey="Herman T">TS Herman</name></author><author><name sortKey="Sweets, Cc" uniqKey="Sweets C">CC Sweets</name></author><author><name sortKey="White, Dm" uniqKey="White D">DM White</name></author><author><name sortKey="Gerner, Ew" uniqKey="Gerner E">EW Gerner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ko, Sh" uniqKey="Ko S">SH Ko</name></author><author><name sortKey="Ueno, T" uniqKey="Ueno T">T Ueno</name></author><author><name sortKey="Yoshimoto, Y" uniqKey="Yoshimoto Y">Y Yoshimoto</name></author><author><name sortKey="Yoo, Js" uniqKey="Yoo J">JS Yoo</name></author><author><name sortKey="Abdel Wahab, Oi" uniqKey="Abdel Wahab O">OI Abdel-Wahab</name></author><author><name sortKey="Abdel Wahab, Z" uniqKey="Abdel Wahab Z">Z Abdel-Wahab</name></author><author><name sortKey="Chu, E" uniqKey="Chu E">E Chu</name></author><author><name sortKey="Pruitt, Sk" uniqKey="Pruitt S">SK Pruitt</name></author><author><name sortKey="Friedman, Hs" uniqKey="Friedman H">HS Friedman</name></author><author><name sortKey="Dewhirst, Mw" uniqKey="Dewhirst M">MW Dewhirst</name></author><author><name sortKey="Tyler, Ds" uniqKey="Tyler D">DS Tyler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, X" uniqKey="Song X">X Song</name></author><author><name sortKey="Kim, Sy" uniqKey="Kim S">SY Kim</name></author><author><name sortKey="Zhou, Z" uniqKey="Zhou Z">Z Zhou</name></author><author><name sortKey="Lagasse, E" uniqKey="Lagasse E">E Lagasse</name></author><author><name sortKey="Kwon, Yt" uniqKey="Kwon Y">YT Kwon</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Krueger, A" uniqKey="Krueger A">A Krueger</name></author><author><name sortKey="Schmitz, I" uniqKey="Schmitz I">I Schmitz</name></author><author><name sortKey="Baumann, S" uniqKey="Baumann S">S Baumann</name></author><author><name sortKey="Krammer, Ph" uniqKey="Krammer P">PH Krammer</name></author><author><name sortKey="Kirchhoff, S" uniqKey="Kirchhoff S">S Kirchhoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kober, Am" uniqKey="Kober A">AM Kober</name></author><author><name sortKey="Legewie, S" uniqKey="Legewie S">S Legewie</name></author><author><name sortKey="Pforr, C" uniqKey="Pforr C">C Pforr</name></author><author><name sortKey="Fricker, N" uniqKey="Fricker N">N Fricker</name></author><author><name sortKey="Eils, R" uniqKey="Eils R">R Eils</name></author><author><name sortKey="Krammer, Ph" uniqKey="Krammer P">PH Krammer</name></author><author><name sortKey="Lavrik, In" uniqKey="Lavrik I">IN Lavrik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Parrish, Ab" uniqKey="Parrish A">AB Parrish</name></author><author><name sortKey="Freel, Cd" uniqKey="Freel C">CD Freel</name></author><author><name sortKey="Kornbluth, S" uniqKey="Kornbluth S">S Kornbluth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xiaofeng, W" uniqKey="Xiaofeng W">W Xiaofeng</name></author><author><name sortKey="Yukai, H" uniqKey="Yukai H">H Yukai</name></author><author><name sortKey="Louis, Df" uniqKey="Louis D">DF Louis</name></author><author><name sortKey="Kam, Mh" uniqKey="Kam M">MH Kam</name></author><author><name sortKey="Leaf, H" uniqKey="Leaf H">H Leaf</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shah, K" uniqKey="Shah K">K Shah</name></author><author><name sortKey="Tung, Ch" uniqKey="Tung C">CH Tung</name></author><author><name sortKey="Yang, K" uniqKey="Yang K">K Yang</name></author><author><name sortKey="Weissleder, R" uniqKey="Weissleder R">R Weissleder</name></author><author><name sortKey="Breakefield, Xo" uniqKey="Breakefield X">XO Breakefield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hardy, S" uniqKey="Hardy S">S Hardy</name></author><author><name sortKey="Kitamura, M" uniqKey="Kitamura M">M Kitamura</name></author><author><name sortKey="Harris Stansil, T" uniqKey="Harris Stansil T">T Harris-Stansil</name></author><author><name sortKey="Dai, U" uniqKey="Dai U">U Dai</name></author><author><name sortKey="Phipps, Ml" uniqKey="Phipps M">ML Phipps</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Sy" uniqKey="Kim S">SY Kim</name></author><author><name sortKey="Song, X" uniqKey="Song X">X Song</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Bartlett, Dl" uniqKey="Bartlett D">DL Bartlett</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wirawan, E" uniqKey="Wirawan E">E Wirawan</name></author><author><name sortKey="Vande Walle, L" uniqKey="Vande Walle L">L Vande Walle</name></author><author><name sortKey="Kersse, K" uniqKey="Kersse K">K Kersse</name></author><author><name sortKey="Cornelis, S" uniqKey="Cornelis S">S Cornelis</name></author><author><name sortKey="Claerhout, S" uniqKey="Claerhout S">S Claerhout</name></author><author><name sortKey="Vanoverberghe, I" uniqKey="Vanoverberghe I">I Vanoverberghe</name></author><author><name sortKey="Roelandt, R" uniqKey="Roelandt R">R Roelandt</name></author><author><name sortKey="De Rycke, R" uniqKey="De Rycke R">R De Rycke</name></author><author><name sortKey="Verspurten, J" uniqKey="Verspurten J">J Verspurten</name></author><author><name sortKey="Declercq, W" uniqKey="Declercq W">W Declercq</name></author><author><name sortKey="Agostinis, P" uniqKey="Agostinis P">P Agostinis</name></author><author><name sortKey="Vanden Berghe, T" uniqKey="Vanden Berghe T">T Vanden Berghe</name></author><author><name sortKey="Lippens, S" uniqKey="Lippens S">S Lippens</name></author><author><name sortKey="Vandenabeele, P" uniqKey="Vandenabeele P">P Vandenabeele</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, H" uniqKey="Li H">H Li</name></author><author><name sortKey="Wang, P" uniqKey="Wang P">P Wang</name></author><author><name sortKey="Sun, Q" uniqKey="Sun Q">Q Sun</name></author><author><name sortKey="Ding, Wx" uniqKey="Ding W">WX Ding</name></author><author><name sortKey="Yin, Xm" uniqKey="Yin X">XM Yin</name></author><author><name sortKey="Sobol, Rw" uniqKey="Sobol R">RW Sobol</name></author><author><name sortKey="Stolz, Db" uniqKey="Stolz D">DB Stolz</name></author><author><name sortKey="Yu, J" uniqKey="Yu J">J Yu</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Itakura, E" uniqKey="Itakura E">E Itakura</name></author><author><name sortKey="Kishi, C" uniqKey="Kishi C">C Kishi</name></author><author><name sortKey="Inoue, K" uniqKey="Inoue K">K Inoue</name></author><author><name sortKey="Mizushima, N" uniqKey="Mizushima N">N Mizushima</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iijima, K" uniqKey="Iijima K">K Iijima</name></author><author><name sortKey="Ohara, M" uniqKey="Ohara M">M Ohara</name></author><author><name sortKey="Seki, R" uniqKey="Seki R">R Seki</name></author><author><name sortKey="Tauchi, H" uniqKey="Tauchi H">H Tauchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hayashi, N" uniqKey="Hayashi N">N Hayashi</name></author><author><name sortKey="Kobayashi, M" uniqKey="Kobayashi M">M Kobayashi</name></author><author><name sortKey="Shamma, A" uniqKey="Shamma A">A Shamma</name></author><author><name sortKey="Morimura, Y" uniqKey="Morimura Y">Y Morimura</name></author><author><name sortKey="Takahashi, C" uniqKey="Takahashi C">C Takahashi</name></author><author><name sortKey="Yamamoto, K" uniqKey="Yamamoto K">K Yamamoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kharbanda, S" uniqKey="Kharbanda S">S Kharbanda</name></author><author><name sortKey="Ren, R" uniqKey="Ren R">R Ren</name></author><author><name sortKey="Pandey, P" uniqKey="Pandey P">P Pandey</name></author><author><name sortKey="Shafman, Td" uniqKey="Shafman T">TD Shafman</name></author><author><name sortKey="Feller, Sm" uniqKey="Feller S">SM Feller</name></author><author><name sortKey="Weichselbaum, Rr" uniqKey="Weichselbaum R">RR Weichselbaum</name></author><author><name sortKey="Kufe, Dw" uniqKey="Kufe D">DW Kufe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Price, Bd" uniqKey="Price B">BD Price</name></author><author><name sortKey="Hughes Davies, L" uniqKey="Hughes Davies L">L Hughes-Davies</name></author><author><name sortKey="Park, Sj" uniqKey="Park S">SJ Park</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Milne, Dm" uniqKey="Milne D">DM Milne</name></author><author><name sortKey="Palmer, Rh" uniqKey="Palmer R">RH Palmer</name></author><author><name sortKey="Campbell, Dg" uniqKey="Campbell D">DG Campbell</name></author><author><name sortKey="Meek, Dw" uniqKey="Meek D">DW Meek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hall, Sr" uniqKey="Hall S">SR Hall</name></author><author><name sortKey="Campbell, Le" uniqKey="Campbell L">LE Campbell</name></author><author><name sortKey="Meek, Dw" uniqKey="Meek D">DW Meek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baudier, J" uniqKey="Baudier J">J Baudier</name></author><author><name sortKey="Delphin, C" uniqKey="Delphin C">C Delphin</name></author><author><name sortKey="Grunwald, D" uniqKey="Grunwald D">D Grunwald</name></author><author><name sortKey="Khochbin, S" uniqKey="Khochbin S">S Khochbin</name></author><author><name sortKey="Lawrence, Jj" uniqKey="Lawrence J">JJ Lawrence</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Milne, Dm" uniqKey="Milne D">DM Milne</name></author><author><name sortKey="Campbell, Dg" uniqKey="Campbell D">DG Campbell</name></author><author><name sortKey="Caudwell, Fb" uniqKey="Caudwell F">FB Caudwell</name></author><author><name sortKey="Meek, Dw" uniqKey="Meek D">DW Meek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Milne, Dm" uniqKey="Milne D">DM Milne</name></author><author><name sortKey="Campbell, Le" uniqKey="Campbell L">LE Campbell</name></author><author><name sortKey="Campbell, Dg" uniqKey="Campbell D">DG Campbell</name></author><author><name sortKey="Meek, Dw" uniqKey="Meek D">DW Meek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jamal, S" uniqKey="Jamal S">S Jamal</name></author><author><name sortKey="Ziff, Eb" uniqKey="Ziff E">EB Ziff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shieh, Sy" uniqKey="Shieh S">SY Shieh</name></author><author><name sortKey="Ikeda, M" uniqKey="Ikeda M">M Ikeda</name></author><author><name sortKey="Taya, Y" uniqKey="Taya Y">Y Taya</name></author><author><name sortKey="Prives, C" uniqKey="Prives C">C Prives</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tibbetts, Rs" uniqKey="Tibbetts R">RS Tibbetts</name></author><author><name sortKey="Brumbaugh, Km" uniqKey="Brumbaugh K">KM Brumbaugh</name></author><author><name sortKey="Williams, Jm" uniqKey="Williams J">JM Williams</name></author><author><name sortKey="Sarkaria, Jn" uniqKey="Sarkaria J">JN Sarkaria</name></author><author><name sortKey="Cliby, Wa" uniqKey="Cliby W">WA Cliby</name></author><author><name sortKey="Shieh, Sy" uniqKey="Shieh S">SY Shieh</name></author><author><name sortKey="Taya, Y" uniqKey="Taya Y">Y Taya</name></author><author><name sortKey="Prives, C" uniqKey="Prives C">C Prives</name></author><author><name sortKey="Abraham, Rt" uniqKey="Abraham R">RT Abraham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alcala, Ma" uniqKey="Alcala M">MA Alcala</name></author><author><name sortKey="Park, K" uniqKey="Park K">K Park</name></author><author><name sortKey="Yoo, J" uniqKey="Yoo J">J Yoo</name></author><author><name sortKey="Lee, Dh" uniqKey="Lee D">DH Lee</name></author><author><name sortKey="Park, Bh" uniqKey="Park B">BH Park</name></author><author><name sortKey="Lee, Bc" uniqKey="Lee B">BC Lee</name></author><author><name sortKey="Bartlett, Dl" uniqKey="Bartlett D">DL Bartlett</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sun, Bk" uniqKey="Sun B">BK Sun</name></author><author><name sortKey="Kim, Jh" uniqKey="Kim J">JH Kim</name></author><author><name sortKey="Nguyen, Hn" uniqKey="Nguyen H">HN Nguyen</name></author><author><name sortKey="Oh, S" uniqKey="Oh S">S Oh</name></author><author><name sortKey="Kim, Sy" uniqKey="Kim S">SY Kim</name></author><author><name sortKey="Choi, Hj" uniqKey="Choi H">HJ Choi</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author><author><name sortKey="Song, Jj" uniqKey="Song J">JJ Song</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, X" uniqKey="Song X">X Song</name></author><author><name sortKey="Kim, Sy" uniqKey="Kim S">SY Kim</name></author><author><name sortKey="Lee, Yj" uniqKey="Lee Y">YJ Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ubersax, Ja" uniqKey="Ubersax J">JA Ubersax</name></author><author><name sortKey="Ferrell, Je" uniqKey="Ferrell J">JE Ferrell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Basu, A" uniqKey="Basu A">A Basu</name></author><author><name sortKey="Haldar, S" uniqKey="Haldar S">S Haldar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kharbanda, S" uniqKey="Kharbanda S">S Kharbanda</name></author><author><name sortKey="Saxena, S" uniqKey="Saxena S">S Saxena</name></author><author><name sortKey="Yoshida, K" uniqKey="Yoshida K">K Yoshida</name></author><author><name sortKey="Pandey, P" uniqKey="Pandey P">P Pandey</name></author><author><name sortKey="Kaneki, M" uniqKey="Kaneki M">M Kaneki</name></author><author><name sortKey="Wang, Q" uniqKey="Wang Q">Q Wang</name></author><author><name sortKey="Cheng, K" uniqKey="Cheng K">K Cheng</name></author><author><name sortKey="Chen, Yn" uniqKey="Chen Y">YN Chen</name></author><author><name sortKey="Campbell, A" uniqKey="Campbell A">A Campbell</name></author><author><name sortKey="Sudha, T" uniqKey="Sudha T">T Sudha</name></author><author><name sortKey="Yuan, Zm" uniqKey="Yuan Z">ZM Yuan</name></author><author><name sortKey="Narula, J" uniqKey="Narula J">J Narula</name></author><author><name sortKey="Weichselbaum, R" uniqKey="Weichselbaum R">R Weichselbaum</name></author><author><name sortKey="Nalin, C" uniqKey="Nalin C">C Nalin</name></author><author><name sortKey="Kufe, D" uniqKey="Kufe D">D Kufe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wei, Y" uniqKey="Wei Y">Y Wei</name></author><author><name sortKey="Pattingre, S" uniqKey="Pattingre S">S Pattingre</name></author><author><name sortKey="Sinha, S" uniqKey="Sinha S">S Sinha</name></author><author><name sortKey="Bassik, M" uniqKey="Bassik M">M Bassik</name></author><author><name sortKey="Levine, B" uniqKey="Levine B">B Levine</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Apoptosis</journal-id><journal-id journal-id-type="iso-abbrev">Apoptosis</journal-id><journal-title-group><journal-title>Apoptosis</journal-title></journal-title-group><issn pub-type="ppub">1360-8185</issn><issn pub-type="epub">1573-675X</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>Boston</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25156145</article-id><article-id pub-id-type="pmc">4196052</article-id><article-id pub-id-type="publisher-id">1028</article-id><article-id pub-id-type="doi">10.1007/s10495-014-1028-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seog-Young</given-names></name><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Dae-Hee</given-names></name><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Xinxin</given-names></name><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Bartlett</surname><given-names>David L.</given-names></name><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Kwon</surname><given-names>Yong Tae</given-names></name><xref ref-type="aff" rid="Aff3"></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Yong J.</given-names></name><address><phone>(412) 623-3268</phone><email>leeyj@upmc.edu</email></address><xref ref-type="aff" rid="Aff2"></xref><xref ref-type="aff" rid="Aff1"></xref></contrib><aff id="Aff1"><label></label>Department of Surgery, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213 USA</aff><aff id="Aff2"><label></label>Department of Pharmacology & Chemical Biology, School of Medicine, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave. Room 1.46C, Pittsburgh, PA 15213, USA</aff><aff id="Aff3"><label></label>Protein Metabolism Medical Research Center and Department of Biomedical Science, College of Medicine, Seoul National University, Seoul, 110-799 Korea</aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>19</volume><issue>11</issue><fpage>1603</fpage><lpage>1615</lpage><permissions><copyright-statement>© The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><p>In this study, we attempted to develop a multimodality approach using chemotherapeutic agent mitomycin C, biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L), and mild hyperthermia to treat colon cancer. For this study, human colon cancer LS174T, LS180, HCT116 and CX-1 cells were infected with secretory TRAIL-armed adenovirus (Ad.TRAIL) and treated with chemotherapeutic agent mitomycin C and hyperthermia. The combinatorial treatment caused a synergistic induction of apoptosis which was mediated through an increase in caspase activation. The combinational treatment promoted the JNK-Bcl-xL-Bak pathway which transmitted the synergistic effect through the mitochondria-dependent apoptotic pathway. JNK signaling led to Bcl-xL phosphorylation at serine 62, dissociation of Bak from Bcl-xL, oligomerization of Bak, alteration of mitochondrial membrane potential, and subsequent cytochrome <italic>c</italic> release. Overexpression of dominant-negative mutant of Bcl-xL (S62A), but not dominant-positive mutant of Bcl-xL (S62D), suppressed the synergistic death effect. Interestingly, Beclin-1 was dissociated from Bcl-xL and overexpression of dominant-negative mutant of Bcl-xL (S62A), but not dominant-positive mutant of Bcl-xL (S62D), suppressed dissociation of Beclin-1 from Bcl-xL. A combinatorial treatment of mitomycin C, Ad.TRAIL and hyperthermia induced Beclin-1 cleavage, but the Beclin-1 cleavage was abolished in Beclin-1 double mutant (D133A/D146A) knock-in HCT116 cells, suppressing the apoptosis induced by the combination therapy. We believe that this study supports the application of the multimodality approach to colon cancer therapy.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mitomycin C</kwd><kwd>Ad.TRAIL</kwd><kwd>Hyperthermia</kwd><kwd>Mitochondria-dependent pathway</kwd><kwd>Bcl-xL</kwd><kwd>Beclin-1</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Science+Business Media New York 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Colorectal cancer is the third leading cause of cancer-related mortality in the world. The main cause of death of patients with colorectal cancer is metastases [<xref ref-type="bibr" rid="CR1">1</xref>]. In the last decade, the medical control of metastatic colorectal cancer has shown remarkable advances. For example, the addition of oxaliplatin and irinotecan to previously existing 5-fluorouracil (5-FU) and leucovorin-based therapies improved the overall median survival of 12 months [<xref ref-type="bibr" rid="CR2">2</xref>], and with the addition of biological targeted therapies such as bevacizumab and cetuximab, the overall median survival rose to 20 months [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. However, systemic chemotherapeutic strategies are currently used only as palliatives—they do not improve long-term survival rates. Therefore, new approaches are necessary to improve the overall median survival for metastatic colorectal cancers such as hepatic colorectal metastases and colorectal peritoneal carcinomatosis.</p><p>Current standard of care for hepatic colorectal metastases and colorectal peritoneal carcinomatosis is hyperthermic isolated hepatic perfusion (HIHP) therapy and hyperthermic intraperitoneal chemotherapy (HIPEC), respectively [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. These therapies are combinatorial treatments of chemotherapeutic agents and mild hyperthermia. We hypothesize that a multimodality [chemotherapeutic agent mitomycin C, biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L), and mild hyperthermia] approach effectively enhances apoptotic death and improves the current standard of care to treat advanced colorectal metastases. To test the hypothesis, in this study, we focus on the effect of multimodality treatment on cell death in in vitro system.</p><p>Chemotherapy is the standard clinical treatment for human cancers. Chemotherapeutics can interact with DNA and activate several intracellular signal pathways including apoptosis [<xref ref-type="bibr" rid="CR11">11</xref>]. Mitomycin C is an antibiotic which has been used as a chemotherapeutic agent in a variety of carcinogenic solid tumors including colon [<xref ref-type="bibr" rid="CR12">12</xref>], breast [<xref ref-type="bibr" rid="CR13">13</xref>], lung [<xref ref-type="bibr" rid="CR14">14</xref>] and bladder [<xref ref-type="bibr" rid="CR15">15</xref>]. Mitomycin C causes cross-links in the DNA molecules of the cells, leading to the formation of DNA interstrands and inhibiting DNA replication and transcription [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Previous reports suggest that mitomycin C produces a consistent response when used as a single agent [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. However, like many other chemotherapeutic agents, mitomycin C may induce resistance to chemotherapy and may target normal cells, thus causing unexpected side effects at therapeutic doses. On the other hand, since mitomycin C offers a suitably low toxicity and can be easily delivered to an outpatient, it seems a reasonable, cost-effective candidate for combinational therapy of colorectal cancer, like irinotecan [<xref ref-type="bibr" rid="CR22">22</xref>], capecitabine [<xref ref-type="bibr" rid="CR23">23</xref>] or 5-FU [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>TRAIL, a highly promising anticancer agent, is a cytokine of the TNF family which binds to the death receptors DR4 [<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR27">27</xref>] and DR5 [<xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR30">30</xref>]. It has the unique ability to induce apoptosis in many transformed cancer cell lines, but not in normal tissue [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Previous studies suggest that TRAIL-induced apoptosis can be enhanced by combinational therapy with several chemotherapeutic agents at non-toxic doses in cancer cells [<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR38">38</xref>]. Nonetheless, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods, and TRAIL-resistant cancer cell populations [<xref ref-type="bibr" rid="CR39">39</xref>]. To solve these limitations, we attempt to develop a secretory TRAIL-armed adenoviral vector.</p><p>Hyperthermia has been explored as an anticancer agent for many decades and is often used with HIPEC. We previously reported that hyperthermia has a synergistic effect with TRAIL in causing cytotoxicity through the mitochondria-dependent pathway [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR43">43</xref>]. Several researchers also reported that hyperthermia acts synergistically with ionizing radiation [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR46">46</xref>], and with a number of chemotherapeutic agents [<xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR49">49</xref>]. We previously reported that hyperthermia triggered down-regulation of c-FLIP<sub>L</sub> (long form of cellular FLICE-inhibitory protein), an anti-apoptotic molecule, in several colon cancer cells [<xref ref-type="bibr" rid="CR50">50</xref>]. c-FLIP splice variants (long and short form) bind to FADD and/or caspase 8/10 and inhibit their activation [<xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR53">53</xref>].</p><p>In this study, we observed that a combinatorial treatment of mitomycin C, adenoviral TRAIL and hyperthermia effectively activates the mitochondrial-dependent apoptotic pathway by activating the JNK-Bcl-xL-Bak pathway, increasing Bak oligomerization, facilitating cytochrome <italic>c</italic> release, promoting dissociation of Beclin-1 from Bcl-xL, and increasing Beclin-1 cleavage.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Cell culture</title><p>The human colon adenocarcinoma line LS174T was kindly provided by Dr. HA Choudry (University of Pittsburgh Medical Center, Pittsburgh, PA, USA) and LS180 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The human colorectal carcinoma HCT116 wild type was obtained from Dr. B Vogelstein (Johns Hopkins University) and CX-1 cell line was obtained from Dr. JM Jessup (National Cancer Institute). Cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Gaithersburg, MD, USA), McCoy’s 5A or RPMI 1640 supplemented with 10 % fetal bovine serum (FBS, Atlanta Biological, Flowery Branch, GA, USA), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco) in a 5 % CO<sub>2</sub> incubator. These adherent cells, except for LS180, were subcultured every 3–4 days by treatment with a trypsin–EDTA solution (Gibco). The LS180 cell line was cultured by following a procedure of ATCC subculturing.</p></sec><sec id="Sec4"><title>Reagents and antibodies</title><p>Mitomycin C and anti-TRAIL antibody were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-PARP, anti-caspase 8/9/3, anti-cleaved caspase 9/3, anti-phosphorylated (Thr183/Tyr185) JNK, anti-JNK, anti-Bcl-xL, anti-COX-IV and anti-human influenza hemagglutinin (HA) antibody were purchased from Cell Signaling (Danvers, MA, USA). Anti-phosphorylated Bcl-xL (S62) antibody was purchased from Millipore (Billerica, MA, USA) and anti-cytochrome <italic>c</italic> antibody and anti-Beclin-1 were from BD Pharmigen (San Jose, CA, USA). Anti-actin antibody and other chemicals were purchased from Sigma (St. Louis, MO, USA).</p></sec><sec id="Sec5"><title>Shuttle vector construction</title><p>pFETZ was kindly provided by Dr. Y He (Immunotherapy Center, Medical College of Georgia, GA, USA) [<xref ref-type="bibr" rid="CR54">54</xref>]. This vector contains cDNA for the extracellular domain of Flt3L, a ligand for Flt3 tyrosine kinase receptor (a.a. 1–81), fused to a leucine zipper domain and the extracellular domain of TRAIL (a.a. 95–281) and expresses a secretable form of TRAIL fusion protein [<xref ref-type="bibr" rid="CR55">55</xref>]. pAdlox-FETZ was made by inserting the SalI/BamHI fragment from pFETZ into SalI/BamHI-cut pAdlox shuttle vector. The complete shuttle vector was co-transfected into CRE8 cells with ψ5 viral genomic DNA for homologous recombination as described below.</p></sec><sec id="Sec6"><title>Adenoviral vector construction</title><p>Recombinant adenovirus was constructed by employing the Cre-lox recombination system [<xref ref-type="bibr" rid="CR56">56</xref>]. The selective cell line CRE8 has a β-actin-based expression cassette driving a Cre recombinase gene with an N-terminal nuclear localization signal stably integrated into 293 cells. Transfections were done by using Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA). Cells were split into T25-flasks 1 day before transfection. For the production of recombinant adenovirus, 2 µg of Adlox/FETZ and 2 µg of ψ5 viral genomic DNA were co-transfected into CRE8 cells in the presence of caspase inhibitor z-VAD-fmk (20 μM). The recombinant adenoviruses were generated by intramolecular homologous recombination between the shuttle vector and ψ5 viral DNA. The new virus had an intact packaging site and carried a recombinant gene. Plaques were harvested, analyzed and purified.</p></sec><sec id="Sec7"><title>Drug treatment</title><p>Drug treatments were accomplished by aspirating the medium and replacing it with new medium containing drugs.</p></sec><sec id="Sec8"><title>Hyperthermia treatment</title><p>Cells cultured in 35 mm or 100 mm dishes were sealed with parafilm and were placed a circulating water bath (Heto, Thomas Scientific, Denmark), which was maintained within 0.02 °C of the desired temperature.</p></sec><sec id="Sec9"><title>Survival assay</title><p>One or 2 days prior to the experiment, human colorectal carcinoma LS174T cells were plated into six well plates. For trypan blue exclusion assay, trypsinized cells were pelleted and resuspended in 0.2 mL of medium, 0.5 mL of 0.4 % trypan blue solution, and 0.3 mL of phosphate-buffered saline solution (PBS). The samples were mixed thoroughly, incubated at room temperature for 15 min, and examined by automated cell counter (LUNA, Logos Biosystems, Annandale, VA, USA). At least 300 cells were counted for each survival determination.</p></sec><sec id="Sec10"><title>Protein extracts and polyacrylamide gel electrophoresis (PAGE)</title><p>Cells were scraped with 1 × Laemmli lysis buffer [including 2.4 M glycerol, 0.14 M Tris (pH 6.8), 0.21 M SDS, and 0.3 mM bromophenol blue] and boiled for 3 min. Protein concentrations were measured with BCA protein assay reagent (Pierce, Rockford, IL, USA). The samples were diluted with 1 × lysis buffer containing 20 mM dithiothreitol (DTT), and an equal amount of protein was loaded on 10–15 % SDS-polyacrylamide gels. SDS-PAGE analysis was performed using a Hoefer gel apparatus.</p></sec><sec id="Sec11"><title>Immunoblot analysis</title><p>Proteins were separated by SDS-PAGE, electrophoretically transferred to nitrocellulose membranes and blocked with 5 % skim milk in TBS-Tween 20 (0.05 %, v/v) for 30 min. The membrane was incubated with primary antibodies for 2 h at room temperature or overnight at 4 °C. Horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized by the enhanced chemi-luminescence protocol (ECL, Amersham, Arlington Heights, IL, USA).</p></sec><sec id="Sec12"><title>Annexin V binding</title><p>The translocation of phosphatidylserine, one of the markers of apoptosis, from the inner to the outer plasma membrane was detected by binding of allophycocyanin (APC)-conjugated Annexin V. LS174T cells were plated into plates, treated with drugs for 24 h and stained with mouse anti-human Annexin V antibody and propidium iodide (PI). The staining was terminated and cells were immediately analyzed by flow cytometry.</p></sec><sec id="Sec13"><title>JC-1 mitochondrial membrane potential assay</title><p>After drug treatment, cells were stained using JC-1 mitochondrial membrane potential detection kit (Invitrogen) for 10 min and analyzed by flow cytometry. Fluorescence intensity was measured with the Accuri C6 flow cytometer (Accuri Cytometers, Inc., San Jose, CA, USA). Results were analyzed with VenturiOne software (Applied Cytometry, Inc., Plano, TX, USA).</p></sec><sec id="Sec14"><title>Cytochrome c release assay</title><p>To determine the release of cytochrome <italic>c</italic> from the mitochondria, LS174T cells growing in 100 mm dishes were used. After drug treatment, mitochondria and cytosolic fractions were prepared from treated cells by using a Mitochondrial Fractionation Kit (Active Motif, Carlsbad, CA, USA) following company instructions and reagents included in the kit. Cytosolic fractions were subjected to SDS-PAGE and analyzed by immunoblotting using anti-cytochrome <italic>c</italic> antibody. Equal loading of the mitochondrial pellets was confirmed with anti-COX IV antibody.</p></sec><sec id="Sec15"><title>Bak oligomerization</title><p>After drug treatment, cells were collected and resuspended in homogenization buffer. The cell suspension was homogenized several times and centrifuged at 1,000×<italic>g</italic> for 10 min at 4 °C to obtain nuclear pellets. Supernatant was transferred to a new 1.5 mL tube and spun at 10,000×<italic>g</italic> for 15 min at 4 °C to pellet the mitochondria. Isolated mitochondrial fractions and cytosolic fractions were cross-linked with 1 mmol/L dithiobis (Pierce) for 1 h at room temperature. After cross-linking, the mitochondria were pelleted and samples were subjected to SDS-PAGE under nondenaturing conditions followed by immunoblotting for Bak.</p></sec><sec id="Sec16"><title>Stable transfection</title><p>Cells stably overexpressing HA-Bcl-xL wild-type (WT) or mutant types were prepared by transfecting CX-1 cells with human Bcl-xL tagged with HA epitope in pCDNA3.1 vector: HA-Bcl-xL WT, HA-Bcl-xL S62A (mutation of serine 62 to alanine), and HA-Bcl-xL S62D (mutation of serine 62 to aspartate; a kind gift from Dr. TC Chambers, University of Arkansas). Cells were maintained in 500 µg/mL G418.</p></sec><sec id="Sec17"><title>Immunoprecipitation</title><p>Briefly, cells were pelleted and lysed by CHAPS buffer with protease inhibitor cocktail. Cell lysates were completely disrupted by repeated aspiration through a 27 gauge needle. Cell debris was removed and protein concentration was determined by BCA Protein Assay Reagent. For immunoprecipitation, 500 µg of lysate was incubated with 1 µg of rabbit anti-Bcl-xL/anti-HA antibody or rabbit IgG at 4 °C overnight, followed by the addition of protein G-agarose beads and rotation at 4 °C for 4 h. Immunoprecipitates were collected by centrifugation and the pellet was dissolved in electrophoresis sample buffer for heat denaturation. The immune complexes were subjected to SDS-PAGE followed by immunoblot analysis.</p></sec><sec id="Sec18"><title>Statistical analysis</title><p>Statistical analysis was carried out using GraphPad InStat 3 software (GraphPad Software, Inc., San Diego, CA, USA). Significance was set at values of *(<italic>p</italic> < 0.05), **(<italic>p</italic> < 0.01), or ***(<italic>p</italic> < 0.001).</p></sec></sec><sec id="Sec19" sec-type="results"><title>Results</title><sec id="Sec20"><title>Characterization of a secretory TRAIL-armed adenoviral vector</title><p>We constructed pAdlox-FETZ shuttle vector which has a CMV promoter-driven secretory human Flt3 ligand-isoleucine zipper-human TRAIL fusion protein gene. This plasmid encoded the secretable form of chimeric TRAIL proteins which were detected in Fig. <xref rid="Fig1" ref-type="fig">1</xref>a. Next, we constructed a secretory TRAIL-armed adenoviral vector (Ad.TRAIL) and characterized the vector. Data from Fig. <xref rid="Fig1" ref-type="fig">1</xref>b shows an expression of TRAIL in Ad.TRAIL infected 293 cells in the absence/presence of caspase inhibitor z-VAD-fmk, which was added to prevent TRAIL-induced apoptosis. Unlike most cancer cell lines, immortalized normal human embryonic kidney 293 cells were resistant to TRAIL. To examine an apoptotic capacity of Ad.TRAIL, human colon adenocarcinoma LS174T cells were infected with various multiplicity of infection (MOI) of Ad.TRAIL and its control adenoviral construct encoding green fluorescent protein (Ad.GFP). As shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>c, Ad.TRAIL induced PARP cleavage, the hallmark feature of apoptosis. TRAIL-induced PARP cleavage was dependent upon MOI. Unlike Ad.TRAIL, Ad.GFP induced minimal apoptosis only at MOI of 100. Next, we investigated the kinetics of apoptosis after Ad.TRAIL infection in human colorectal carcinoma HCT116 and LS174T cells. Figure <xref rid="Fig1" ref-type="fig">1</xref>d shows that PARP cleavage occurred 24 h after infection in both cell lines.<fig id="Fig1"><label>Fig. 1</label><caption><p>Production of secretory TRAIL and its cytotoxicity. <bold>a</bold> 293 cells were non-transfected (lane 1), or transfected with 4 µg pAdlox empty vector (lane 2) or pAdlox-FETZ vector (lane 3, 4) and then incubated for 48 h. After incubation, 30 µg of cell lysate protein (lane 1, 2, 3, and 4) or 30 µL of cell culture medium (lane 5, 6) were immunoblotted with anti-TRAIL antibody. <bold>b</bold> 293 cells were infected with Ad.TRAIL (MOI 10) in the presence/absence of caspase inhibitor (20 µM). Cell lysates were prepared in lysis buffer and immunoblotted with anti-TRAIL. <bold>c</bold> LS174T cells were infected by various MOI of Ad.TRAIL or Ad.GFP for 24 h and harvested. Cell lysates were immunoblotted with anti-PARP antibody. <bold>d</bold> HCT116 and LS174T cells were infected with Ad.TRAIL (MOI 50) and harvested at various time points. Cell lysates were immunoblotted with anti-PARP antibody. Actin was used as an internal standard</p></caption><graphic xlink:href="10495_2014_1028_Fig1_HTML" id="MO1"></graphic></fig></p></sec><sec id="Sec21"><title>Synergistic induction of apoptosis by Ad.TRAIL in combination with mitomycin C and hyperthermia</title><p>To investigate the effect on cell viability of the application of Ad.TRAIL in combination with mitomycin C and hyperthermia, LS174T cells were infected with Ad.TRAIL (MOI 25) and treated with 5 µg/mL mitomycin C for 24 h. After treatment, the cells were heated at 42 °C for 1 h and incubated at 37 °C for 3 h and then cell viability was determined by trypan blue dye exclusion assay. As shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>a, synergistic cytotoxic effect was observed in Ad.TRAIL + mitomycin C or Ad.TRAIL + mitomycin C + hyperthermia compared with any single treatment (<italic>p</italic> < 0.05). We further investigated whether the combinatorial treatment-induced cytotoxicity was associated with apoptosis. Data from the flow cytometry assay demonstrate that the combinatorial treatment-induced cytotoxicity was associated with apoptosis (Figs. <xref rid="Fig2" ref-type="fig">2</xref>b, c); apoptotic death cells were observed in the lower right quadrant (early apoptotic death) and the upper right quadrant (late apoptotic death) of the plots. The results from Figs. <xref rid="Fig2" ref-type="fig">2</xref>b, c clearly demonstrate that apoptosis was time-dependent during combined treatment. Figures <xref rid="Fig2" ref-type="fig">2</xref>b, c clearly show that treatment with Ad.TRAIL in combination with mitomycin C and hyperthermia enhanced synergistic induction of apoptotic death. These synergistic effects were due to an increased activation (cleavage) of caspase 8/9/3 and thus, the hallmark feature of apoptosis, PARP cleavage (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a). Similar results were observed in LS180, CX-1 and HCT116 cell lines (Figs. <xref rid="Fig3" ref-type="fig">3</xref>b, c, d). These results indicate that synergistic induction of apoptosis by combinatorial treatment with mitomycin C/Ad.TRAIL/hyperthermia is mediated through an increase in caspase activation.<fig id="Fig2"><label>Fig. 2</label><caption><p>Synergistic induction of cytotoxicity by treatment with Ad.TRAIL in combination with mitomycin C and hyperthermia in LS174T cells. LS174T cells were treated with Ad.TRAIL (MOI 25) or/and mitomycin C (5 µg/mL) for 24 h and exposed to normothermia (37 °C) or hyperthermia (42 °C) for 1 h, and then incubated for 3 h at 37 °C. <bold>a</bold> Cell survival was analyzed by the trypan blue dye exclusion assay. <bold>b</bold> Cells were stained with fluorescein isothiocyanate (FITC)-Annexin V and propidium iodide (PI). <bold>c</bold> Cells were treated with Ad.TRAIL (MOI 25) and mitomycin C (5 µg/mL) for 4, 8, and 16 h and exposed to hyperthermia (42 °C) for 1 h, and then incubated for 3 h at 37 °C. Apoptosis was detected by the flow-cytometric assay</p></caption><graphic xlink:href="10495_2014_1028_Fig2_HTML" id="MO2"></graphic></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Synergistic induction of apoptosis by treatment with Ad.TRAIL in combination with mitomycin C and hyperthermia in colon cancer cells. LS174T (<bold>a</bold>), LS180 (<bold>b</bold>), CX-1 (<bold>c</bold>) and HCT116 (<bold>d</bold>) cells were treated with Ad.TRAIL (MOI 25 or 50) or/and mitomycin C (3.5 or 5 µg/mL) for 24 h and exposed to normothermia (37 °C) or hyperthermia (42 °C) for 1 h, and then incubated for 3 h at 37 °C. After treatment, the cleavage of caspase 8/9/3 or PARP was detected by immunoblotting. Actin was used to confirm the equal amount of proteins loaded in each lane</p></caption><graphic xlink:href="10495_2014_1028_Fig3_HTML" id="MO3"></graphic></fig></p></sec><sec id="Sec22"><title>Role of the JNK-Bcl-xL-Bak pathway in the combinatorial treatment-induced apoptosis</title><p>We previously reported that the JNK-Bcl-xL pathway plays an important role in the synergistic effect on apoptosis of treatment with multiple cytotoxic agents [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. This possibility was examined during treatment with mitomycin C/Ad.TRAIL/hyperthermia. Phosphorylation of JNK and Bcl-xL was observed during treatment with mitomycin C/Ad.TRAIL/hyperthermia in LS174T cells (Fig. <xref rid="Fig4" ref-type="fig">4</xref>a). Even with treatment with only mitomycin C, phosphorylation of JNK and Bcl-xL was detected. Moreover, an increase in phosphorylation was observed during combinatorial therapy. Data from immunoprecipitation assay show that the combinatorial treatment induced the dissociation of Bak from Bcl-xL (Fig. <xref rid="Fig4" ref-type="fig">4</xref>b). We previously reported that phosphorylation of Bcl-xL alters the interactions between Bcl-xL and Bax and then leads to Bax oligomerization [<xref ref-type="bibr" rid="CR43">43</xref>]. Since the presence of Bax was not detected in LS174T cells (data not shown), we examined Bak oligomerization. Bak oligomerization occurred during treatment with Ad.TRAIL in combination with mitomycin C with/without hyperthermia (Fig. <xref rid="Fig4" ref-type="fig">4</xref>c). Oligomerized Bak may bind to the mitochondria, altering mitochondrial membrane potential (Fig. <xref rid="Fig4" ref-type="fig">4</xref>d) and causing a cytochrome c release (Fig. <xref rid="Fig4" ref-type="fig">4</xref>e).<fig id="Fig4"><label>Fig. 4</label><caption><p>Ad.TRAIL in combination with mitomycin C and hyperthermia-induced activation of the JNK-Bcl-xL pathway, Bak oligomerization, mitochondrial membrane potential change and cytochrome <italic>c</italic> release. LS174T cells were treated with Ad.TRAIL (MOI 25) or/and mitomycin C (5 µg/mL) for 24 h and exposed to normothermia (37 °C) or hyperthermia (42 °C) for 1 h, and then incubated for 3 h at 37 °C. <bold>a</bold> After treatment, cell lysates containing equal amounts of protein were separated by SDS-PAGE and immunoblotted with anti-phospho-JNK, anti-JNK, anti-phospho Bcl-xL or anti-Bcl-xL antibody. <bold>b</bold> Cell lysates were immunoprecipitated with anti-Bcl-xL antibody or IgG and immunoblotted with anti-Bak antibody. The presence of Bcl-xL and Bak in the lysates was examined. Asterisk (*) is IgG light chain (LC). <bold>c</bold> Mitochondrial and cytosolic fractions were isolated and were cross-linked with 1 M DSP (dithiobis, succinimidyl propionate) for 30 min and then subjected to immunoblotting with anti-Bak antibody. Bak monomer (×1) and multimer (×2, ×3) are indicated. COX IV and actin were shown as an internal standard of mitochondrial fraction and cytosolic fraction, respectively. <bold>d</bold> Cells were stained with JC-1 and then analyzed by flow cytometry. <bold>e</bold> Cytochrome <italic>c</italic> release into cytosol was determined by immunoblotting for cytochrome <italic>c</italic> in the cytosolic fraction. Actin was used to confirm the equal amount of proteins loaded</p></caption><graphic xlink:href="10495_2014_1028_Fig4_HTML" id="MO4"></graphic></fig></p></sec><sec id="Sec23"><title>Alteration of interactions between Bcl-xL and Beclin-1 and cleavage of Beclin-1 during the combinatorial treatment</title><p>To examine whether phosphorylation of the S62 residue on Bcl-xL is important for apoptosis, CX-1 cells were stably transfected with plasmid containing HA-Bcl-xL WT, phosphor-defective HA-Bcl-xL S62A or phosphor-mimic HA-Bcl-xL S62D. Figure <xref rid="Fig5" ref-type="fig">5</xref>a shows that HA-Bcl-xL S62A, but not HA-Bcl-xL WT and HA-Bcl-xL S62D, inhibited apoptosis. These results suggest that the phosphorylation of Bcl-xL plays an important role in the combinatorial treatment-induced apoptosis. We previously reported that phosphorylation of Bcl-xL affects interaction between Bcl-xL and Beclin-1, causing dissociation of Beclin-1 from Bcl-xL [<xref ref-type="bibr" rid="CR57">57</xref>]. Data from immunoprecipitation assay show that overexpression of dominant-negative mutant type of Bcl-xL S62A, but not wild type Bcl-xL WT or dominant-positive mutant type of Bcl-xL S62D, suppressed the dissociation of Beclin-1 from Bcl-xL (Fig. <xref rid="Fig5" ref-type="fig">5</xref>b). Several researchers reported that Beclin-1 has two cleavage sites at D133 and D146 residues [<xref ref-type="bibr" rid="CR58">58</xref>] and that Beclin-1 is cleaved by caspase 8, and C-terminal fragment of Beclin-1 localizes at the mitochondria and then induces cytochrome <italic>c</italic> release [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Figure <xref rid="Fig6" ref-type="fig">6</xref>a shows that the combinatorial treatment enhanced Beclin-1 cleavage. On Fig. <xref rid="Fig6" ref-type="fig">6</xref>b, data from Beclin-1 double mutant (D133A/D146A) knock-in HCT116 cells show suppression of cleavage of PARP and caspase 8/9/3 (apoptosis). Beclin-1, a mammalian homolog of yeast autophagy-related protein 6 (Atg6), functions in autophagy by initiating autophagosome formation [<xref ref-type="bibr" rid="CR60">60</xref>]. However, it has been suggested that crosstalk between apoptosis and autophagy is associated with caspase-mediated cleavage of Beclin-1 which destroys its pro-autophagic activity and can then amplify mitrochondrion-mediated apoptosis through the cleaved C-terminal fragment [<xref ref-type="bibr" rid="CR58">58</xref>]. Our data suggest that the combinatorial treatment-induced synergistic apoptotic death is mediated through Beclin-1 cleavage.<fig id="Fig5"><label>Fig. 5</label><caption><p>Role of Bcl-xL in apoptosis. CX-1 cells were stably transfected with HA-Bcl-xL WT, HA-Bcl-xL S62A or HA-Bcl-xL S62D plasmid and then treated with Ad.TRAIL (MOI 25) and/or mitomycin C (5 µg/mL) for 24 h and exposed to normothermia (37 °C) or hyperthermia (42 °C) for 1 h, and then incubated for 3 h at 37 °C. <bold>a</bold> After treatment, lysates containing equal amounts of protein were separated by SDS-PAGE and PARP cleavage was detected by immunoblotting. Actin was used as an internal standard. <bold>b</bold> Cell lysates were immunoprecipitated with anti-HA antibody or mock antibody (IgG) and immunoblotted with anti-Beclin-1 or anti-HA antibody (<italic>upper panels</italic>). The presence of Beclin-1 and actin in the lysates was examined (<italic>lower panels</italic>)</p></caption><graphic xlink:href="10495_2014_1028_Fig5_HTML" id="MO5"></graphic></fig><fig id="Fig6"><label>Fig. 6</label><caption><p>Role of Beclin-1 in Ad.TRAIL in combination with mitomycin C and hyperthermia-induced cell death. LS174T, HCT116 and HCT116 Beclin-1 knock-in (D133A/D146A) cells were treated with Ad.TRAIL (MOI 25) or/and mitomycin C (3.5 or 5 µg/mL) for 24 h and exposed to normothermia (37 °C) or hyperthermia (42 °C) for 1 h, and then incubated for 3 h at 37 °C. <bold>a</bold> LS174T cell lysates were immunoblotted by Beclin-1 antibody. <italic>Arrows</italic> indicate cleaved Beclin-1. <bold>b</bold> Parental HCT116 (HCT116 WT) and HCT116 D133A/D146A cell lysates were immunoblotted with anti-PARP, anti-caspase 8/9/3, or anti-Beclin-1 antibody. Actin was shown as an internal standard</p></caption><graphic xlink:href="10495_2014_1028_Fig6_HTML" id="MO6"></graphic></fig></p></sec></sec><sec id="Sec24" sec-type="discussion"><title>Discussion</title><p>Several conclusions can be drawn upon consideration of the data presented here. First, a combinatorial treatment of Ad.TRAIL, mitomycin C and hyperthermia synergistically induces apoptosis. Second, the JNK-Bcl-xL-Bak pathway plays an important role in the apoptosis through activating the mitochondria-dependent pathway. Third, a combinatorial treatment of Ad.TRAIL, mitomycin C and hyperthermia induces dissociation of Beclin-1 from Bcl-xL and promotes Beclin-1 cleavage which results in enhancement of apoptosis.</p><p>The DNA damage surveillance network may orchestrate cellular responses to mitomycin C-induced DNA damage through the recruitment of DNA damage sensing molecules, transducer and effector proteins [<xref ref-type="bibr" rid="CR61">61</xref>]. Ataxia telangiectasia mutated (ATM) and Nijmegen breakage syndrome (NBS1) cooperatively sense DNA damage and post-translationally modify transducers such as BRCA1 (early-onset familial breast and ovarian cancer), MDC1 (mediator of DNA damage checkpoint 1), 53BP1 (p53-binding protein 1), and c-Abl [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. These modified transducer proteins amplify and transduce the signals to downstream effectors such as H2AX, p53, Chk2 and JNK [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR72">72</xref>]. It is possible that mitomycin C-activated JNK is mediated through the ATM-c-Abl signal transduction pathway. This possibility needs to be further investigated.</p><p>We previously reported that Bcl-xL undergoes phosphorylation in response to treatment with oxaliplatin, TRAIL/mapatumumab and hyperthermia [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR73">73</xref>–<xref ref-type="bibr" rid="CR75">75</xref>]. Bcl-xL phosphorylation requires activated JNK, which can recognize a proline residue on the carboxyl side of the phospho-acceptor [<xref ref-type="bibr" rid="CR76">76</xref>]. Some studies reported Bcl-xL phosphorylation to occur on serine 62, while others reported it to occur on threonines 47 and 115 [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. This study with site-directed mutagenesis at Ser-62 showed that cells expressing a validated phospho-defective Bcl-xL mutant are resistant to the combinatorial treatment of Ad.TRAIL, mitomycin C and hyperthermia-induced apoptosis, whereas cells expressing a phospho-mimic Bcl-xL are sensitive to the combinatorial treatment-induced apoptosis, indicating that phosphorylation at Ser-62 is a key regulatory mechanism for antagonizing anti-apoptotic function in the combinatorial treatment.</p><p>Previous studies have shown that JNK1-mediated phosphorylation of Bcl-2 at residues T69, S70, and S87 is required for dissociation of Bcl-2 from Beclin-1 and autophagy activation [<xref ref-type="bibr" rid="CR79">79</xref>]. Unlike Bcl-2, data from Fig. <xref rid="Fig5" ref-type="fig">5</xref>b suggests that for Bcl-xL, phosphorylation only at residue S62 may be sufficient for Bcl-xL dissociation from Beclin-1. It was reported that D133 and D146 of Beclin-1 are cleaved by caspase 8 during apoptosis [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Caspase 8-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Studies with the caspase 8-resistant Beclin-1 knockin cell line clearly demonstrate that the combinatorial treatment-induced Beclin-1 cleavage and apoptosis were reduced (Fig. <xref rid="Fig6" ref-type="fig">6</xref>b), and Beclin-1’s autophagy-promoting function was restored (data not shown) in Beclin-1 KI HCT116 cells.</p><p>We reported that hyperthermia has a synergistic effect with TRAIL in causing apoptosis [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR42">42</xref>]. We also reported that hyperthermia triggers down-regulation of c-FLIP<sub>L</sub> (long form of cellular FLICE-inhibitory protein), an anti-apoptotic molecule, through ubquitination in several colon cancer cell lines [<xref ref-type="bibr" rid="CR50">50</xref>]. It has been found that c-FLIP splice variants (long and short form) bind to FADD and/or caspase 8/10 and inhibit their activation [<xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR53">53</xref>]. Thus, down-regulation of c-FLIP<sub>L</sub> is probably responsible for hyperthermia-enhanced TRAIL cytotoxicity. Interestingly, long-term pretreatment with TRAIL by expressing TRAIL from Ad.TRAIL showed a minimal synergistic effect with hyperthermia, even though down-regulation of c-FLIP<sub>L</sub> was observed (data not shown). This may be due to the activation of TRAIL-associated death signals prior to hyperthermia. This possibility needs to be further studied.</p><p>Our data illustrate that a combinatorial treatment of Ad.TRAIL, mitomycin C and mild hyperthermia synergistically induces apoptosis and effectively activates the mitochondria-dependent apoptotic pathway by activating the JNK-Bcl-xL-Bak pathway. Moreover, our data suggest that Beclin-1 is dissociated from phosphorylated Bcl-xL and cleaved during treatment with Ad.TRAIL, mitomycin C and hyperthermia. The cleavage of Beclin-1 promoted the combinatorial treatment-induced apoptotic death. The studies presented here further elucidate a crosstalk between the JNK-Bcl-xL-Bak pathway and the Bcl-xL/Beclin-1-mediated pathway during treatment with Ad.TRAIL, mitomycin C and hyperthermia. A greater understanding of these interactions may be critical for enhancing the combinatorial treatment.
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>Ad.TRAIL</term><def><p>TRAIL-armed adenovirus</p></def></def-item><def-item><term>APC</term><def><p>Allophycocyanin</p></def></def-item><def-item><term>ATM</term><def><p>Ataxia telangiectasia mutated</p></def></def-item><def-item><term>53BP1</term><def><p>p53-binding protein 1</p></def></def-item><def-item><term>BAX</term><def><p>Bcl-2–associated X protein</p></def></def-item><def-item><term>Bcl-xL</term><def><p>B-cell lymphoma-extra large</p></def></def-item><def-item><term>BRCA1</term><def><p>Early-onset familial breast and ovarian cancer</p></def></def-item><def-item><term>c-FLIP<sub>L</sub></term><def><p>Long form of cellular FLICE-inhibitory protein</p></def></def-item><def-item><term>Chk2</term><def><p>Checkpoint kinase 2</p></def></def-item><def-item><term>COX</term><def><p>Cyclooxygenase</p></def></def-item><def-item><term>CRE8</term><def><p>Cre-expressing 293 cells</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco’s modified eagle medium</p></def></def-item><def-item><term>DR4</term><def><p>Death receptor 4</p></def></def-item><def-item><term>DR5</term><def><p>Death receptor 5</p></def></def-item><def-item><term>DTT</term><def><p>Dithiothreitol</p></def></def-item><def-item><term>EDTA</term><def><p>Ethylenediaminetetraacetic acid</p></def></def-item><def-item><term>5-FU</term><def><p>5-fluorouracil</p></def></def-item><def-item><term>FADD</term><def><p>Fas-Associated protein with Death Domain</p></def></def-item><def-item><term>FBS</term><def><p>Fetal bovine serum</p></def></def-item><def-item><term>FLICE</term><def><p>FADD-like interleukin-1 beta-converting enzyme</p></def></def-item><def-item><term>Flt3</term><def><p>fms-related tyrosine kinase 3</p></def></def-item><def-item><term>Flt3L</term><def><p>Ligand for Flt3</p></def></def-item><def-item><term>HA</term><def><p>Hemagglutinin</p></def></def-item><def-item><term>HIPEC</term><def><p>Hyperthermic intraperitoneal chemotherapy</p></def></def-item><def-item><term>JNK</term><def><p>c-Jun NH2-terminal kinase</p></def></def-item><def-item><term>KI</term><def><p>Knock-in</p></def></def-item><def-item><term>MDC1</term><def><p>Mediator of DNA damage checkpoint 1</p></def></def-item><def-item><term>NBS1</term><def><p>Nijmegen breakage syndrome</p></def></def-item><def-item><term>PARP</term><def><p>Poly (ADP-ribose) polymerase</p></def></def-item><def-item><term>PBS</term><def><p>Phosphate-buffered saline solution</p></def></def-item><def-item><term>PI</term><def><p>Propidium iodide</p></def></def-item><def-item><term>RPMI</term><def><p>Roswell Park Memorial Institute medium</p></def></def-item><def-item><term>SDS</term><def><p>Sodium dodecyl sulfate</p></def></def-item><def-item><term>PAGE</term><def><p>Polyacrylamide gel electrophoresis</p></def></def-item><def-item><term>BH3</term><def><p>Bcl-2 homology domain 3</p></def></def-item><def-item><term>TNF</term><def><p>Tumor necrosis factor</p></def></def-item><def-item><term>TRAIL</term><def><p>Tumor necrosis factor-related apoptosis-inducing ligand</p></def></def-item><def-item><term>WT</term><def><p>Wild-type</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p>Seog-Young Kim and Dae-Hee Lee have contributed equally to this work.</p></fn></fn-group><ack><p>This work was supported by NCI Grant R01CA140554 (Y.J.L.) and the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning (NRF-2013R1A2A2A01014170, Y.T.K.). This project used the UPCI Core Facility and was supported in part by award P30CA047904.</p><sec id="d30e1103"><title>Conflict of interest</title><p>The authors declare no competing financial interests.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>TC</given-names></name><name><surname>Esquivel</surname><given-names>J</given-names></name><name><surname>Pelz</surname><given-names>JO</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name></person-group><article-title>Summary of current therapeutic options for peritoneal metastases from colorectal cancer</article-title><source>J Surg Oncol</source><year>2013</year><volume>107</volume><fpage>566</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1002/jso.23189</pub-id><pub-id pub-id-type="pmid">22688776</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Maroun</surname><given-names>JA</given-names></name><name><surname>Ackland</surname><given-names>SP</given-names></name><name><surname>Locker</surname><given-names>PK</given-names></name><name><surname>Pirotta</surname><given-names>N</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group</article-title><source>N Eng J Med</source><year>2000</year><volume>343</volume><fpage>905</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1056/NEJM200009283431302</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurwitz</surname><given-names>H</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name><name><surname>Cartwright</surname><given-names>T</given-names></name><name><surname>Hainsworth</surname><given-names>J</given-names></name><name><surname>Heim</surname><given-names>W</given-names></name><name><surname>Berlin</surname><given-names>J</given-names></name><name><surname>Baron</surname><given-names>A</given-names></name><name><surname>Griffing</surname><given-names>S</given-names></name><name><surname>Holmgren</surname><given-names>E</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Fyfe</surname><given-names>G</given-names></name><name><surname>Rogers</surname><given-names>B</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name><name><surname>Kabbinavar</surname><given-names>F</given-names></name></person-group><article-title>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2335</fpage><lpage>2342</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa032691</pub-id><pub-id pub-id-type="pmid">15175435</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colucci</surname><given-names>G</given-names></name><name><surname>Gebbia</surname><given-names>V</given-names></name><name><surname>Paoletti</surname><given-names>G</given-names></name><name><surname>Giuliani</surname><given-names>F</given-names></name><name><surname>Caruso</surname><given-names>M</given-names></name><name><surname>Gebbia</surname><given-names>N</given-names></name><name><surname>Cartenì</surname><given-names>G</given-names></name><name><surname>Agostara</surname><given-names>B</given-names></name><name><surname>Pezzella</surname><given-names>G</given-names></name><name><surname>Manzione</surname><given-names>L</given-names></name><name><surname>Borsellino</surname><given-names>N</given-names></name><name><surname>Misino</surname><given-names>A</given-names></name><name><surname>Romito</surname><given-names>S</given-names></name><name><surname>Durini</surname><given-names>E</given-names></name><name><surname>Cordio</surname><given-names>S</given-names></name><name><surname>Di Seri</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Maiello</surname><given-names>E</given-names></name><name><surname>Montemurro</surname><given-names>S</given-names></name><name><surname>Cramarossa</surname><given-names>A</given-names></name><name><surname>Lorusso</surname><given-names>V</given-names></name><name><surname>Di Bisceglie</surname><given-names>M</given-names></name><name><surname>Chiarenza</surname><given-names>M</given-names></name><name><surname>Valerio</surname><given-names>MR</given-names></name><name><surname>Guida</surname><given-names>T</given-names></name><name><surname>Leonardi</surname><given-names>V</given-names></name><name><surname>Pisconti</surname><given-names>S</given-names></name><name><surname>Rosati</surname><given-names>G</given-names></name><name><surname>Carrozza</surname><given-names>F</given-names></name><name><surname>Nettis</surname><given-names>G</given-names></name><name><surname>Valdesi</surname><given-names>M</given-names></name><name><surname>Filippelli</surname><given-names>G</given-names></name><name><surname>Fortunato</surname><given-names>S</given-names></name><name><surname>Mancarella</surname><given-names>S</given-names></name><name><surname>Brunetti</surname><given-names>C</given-names></name></person-group><article-title>Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>4866</fpage><lpage>4875</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.07.113</pub-id><pub-id pub-id-type="pmid">15939922</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Díaz-Rubio</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Koski</surname><given-names>S</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>TS</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Couture</surname><given-names>F</given-names></name><name><surname>Sirzén</surname><given-names>F</given-names></name><name><surname>Saltz</surname><given-names>L</given-names></name></person-group><article-title>Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2006</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.9898</pub-id><pub-id pub-id-type="pmid">18421053</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porschen</surname><given-names>R</given-names></name><name><surname>Arkenau</surname><given-names>HT</given-names></name><name><surname>Kubicka</surname><given-names>S</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><name><surname>Seufferlein</surname><given-names>T</given-names></name><name><surname>Freier</surname><given-names>W</given-names></name><name><surname>Kretzschmar</surname><given-names>A</given-names></name><name><surname>Graeven</surname><given-names>U</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Hinke</surname><given-names>A</given-names></name><name><surname>Schmiegel</surname><given-names>W</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name></person-group><article-title>Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>4217</fpage><lpage>4223</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.2684</pub-id><pub-id pub-id-type="pmid">17548840</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Díaz-Rubio</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Koski</surname><given-names>S</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>TS</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Couture</surname><given-names>F</given-names></name><name><surname>Sirzén</surname><given-names>F</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name></person-group><article-title>Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2013</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.9930</pub-id><pub-id pub-id-type="pmid">18421054</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Brunetti</surname><given-names>I</given-names></name><name><surname>Pfanner</surname><given-names>E</given-names></name><name><surname>Allegrini</surname><given-names>G</given-names></name><name><surname>Barbara</surname><given-names>C</given-names></name><name><surname>Crinò</surname><given-names>L</given-names></name><name><surname>Benedetti</surname><given-names>G</given-names></name><name><surname>Evangelista</surname><given-names>W</given-names></name><name><surname>Fanchini</surname><given-names>L</given-names></name><name><surname>Cortesi</surname><given-names>E</given-names></name><name><surname>Picone</surname><given-names>V</given-names></name><name><surname>Vitello</surname><given-names>S</given-names></name><name><surname>Chiara</surname><given-names>S</given-names></name><name><surname>Granetto</surname><given-names>C</given-names></name><name><surname>Porcile</surname><given-names>G</given-names></name><name><surname>Fioretto</surname><given-names>L</given-names></name><name><surname>Orlandini</surname><given-names>C</given-names></name><name><surname>Andreuccetti</surname><given-names>M</given-names></name><name><surname>Masi</surname><given-names>G</given-names></name></person-group><article-title>Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>1670</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.0928</pub-id><pub-id pub-id-type="pmid">17470860</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeh</surname><given-names>HJ</given-names><suffix>3rd</suffix></name><name><surname>Brown</surname><given-names>CK</given-names></name><name><surname>Holtzman</surname><given-names>MP</given-names></name><name><surname>Egorin</surname><given-names>MJ</given-names></name><name><surname>Holleran</surname><given-names>JL</given-names></name><name><surname>Potter</surname><given-names>DM</given-names></name><name><surname>Bartlett</surname><given-names>DL</given-names></name></person-group><article-title>A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer</article-title><source>Ann Surg Oncol</source><year>2009</year><volume>16</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1245/s10434-008-0179-5</pub-id><pub-id pub-id-type="pmid">19034580</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceelen</surname><given-names>WP</given-names></name></person-group><article-title>Current management of peritoneal carcinomatosis from colorectal cancer</article-title><source>Minerva Chir</source><year>2013</year><volume>68</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">23584267</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddik</surname><given-names>ZH</given-names></name></person-group><article-title>Cisplatin: mode of cytotoxic action and molecular basis of resistance</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>7265</fpage><lpage>7279</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206933</pub-id><pub-id pub-id-type="pmid">14576837</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>G</given-names></name><name><surname>Dickson</surname><given-names>JL</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Norman</surname><given-names>AR</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Hill</surname><given-names>ME</given-names></name><name><surname>Price</surname><given-names>TJ</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Tebbutt</surname><given-names>N</given-names></name></person-group><article-title>Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan</article-title><source>Br J Cancer</source><year>2005</year><volume>93</volume><fpage>510</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6602733</pub-id><pub-id pub-id-type="pmid">16091760</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Tokudome</surname><given-names>N</given-names></name><name><surname>Sugihara</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Seto</surname><given-names>Y</given-names></name><name><surname>Iwase</surname><given-names>T</given-names></name><name><surname>Hatake</surname><given-names>K</given-names></name></person-group><article-title>Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes</article-title><source>Breast Cancer</source><year>2009</year><volume>16</volume><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1007/s12282-009-0093-0</pub-id><pub-id pub-id-type="pmid">19205831</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghmans</surname><given-names>T</given-names></name><name><surname>Gourcerol</surname><given-names>D</given-names></name><name><surname>Lafitte</surname><given-names>JJ</given-names></name><name><surname>Kotsori</surname><given-names>K</given-names></name><name><surname>Paesmans</surname><given-names>M</given-names></name><name><surname>Scherpereel</surname><given-names>A</given-names></name><name><surname>Leclercq</surname><given-names>N</given-names></name><name><surname>Sculier</surname><given-names>JP</given-names></name></person-group><article-title>Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study</article-title><source>Lung Cancer</source><year>2008</year><volume>61</volume><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2008.01.011</pub-id><pub-id pub-id-type="pmid">18313792</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname><given-names>A</given-names></name><name><surname>Mostafid</surname><given-names>H</given-names></name></person-group><article-title>Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer</article-title><source>BJU Int</source><year>2009</year><volume>103</volume><fpage>726</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.08094.x</pub-id><pub-id pub-id-type="pmid">19007379</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>VN</given-names></name><name><surname>Szybalski</surname><given-names>W</given-names></name></person-group><article-title>Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA</article-title><source>Science</source><year>1964</year><volume>145</volume><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1126/science.145.3627.55</pub-id><pub-id pub-id-type="pmid">14162693</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>VN</given-names></name><name><surname>Szybalski</surname><given-names>W</given-names></name></person-group><article-title>A molecular mechanism of mitomycin action: linking of complementary DNA strands</article-title><source>Proc Natl Acad Sci USA</source><year>1963</year><volume>50</volume><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1073/pnas.50.2.355</pub-id><pub-id pub-id-type="pmid">14060656</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>SK</given-names></name><name><surname>Comis</surname><given-names>RL</given-names></name></person-group><article-title>The integration of chemotherapy into a combined modality approach for cancer treatment IV: pancreatic adenocarcinoma</article-title><source>Cancer Treat Rev</source><year>1975</year><volume>2</volume><fpage>193</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/S0305-7372(75)80003-X</pub-id><pub-id pub-id-type="pmid">1104163</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittington</surname><given-names>RM</given-names></name><name><surname>Close</surname><given-names>HP</given-names></name></person-group><article-title>Clinical experience with mitomycin C</article-title><source>Cancer Chemother Rep</source><year>1970</year><volume>54</volume><fpage>195</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">4334088</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>SK</given-names></name></person-group><article-title>Mitomycin C—clinical brochure</article-title><source>Cancer Chemother Rep</source><year>1968</year><volume>1</volume><fpage>99</fpage><lpage>114</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>GE</given-names></name><name><surname>Bross</surname><given-names>ID</given-names></name><name><surname>Ausmans</surname><given-names>R</given-names></name><name><surname>Nadler</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Slack</surname><given-names>N</given-names></name><name><surname>Rimm</surname><given-names>AA</given-names></name></person-group><article-title>Effects of mitomycin C in 346 patients with advanced cancer. Eastern Clinical Drug Evaluation Program</article-title><source>Cancer Chemother Rep</source><year>1968</year><volume>52</volume><fpage>675</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">5753587</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kano</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Akutsu</surname><given-names>M</given-names></name><name><surname>Suda</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>S</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name></person-group><article-title>Effects of CPT-11 in combination with other anti-cancer agents in culture</article-title><source>Int J Cancer</source><year>1992</year><volume>50</volume><fpage>604</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910500420</pub-id><pub-id pub-id-type="pmid">1537625</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>N</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Fukase</surname><given-names>Y</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Yoshikubo</surname><given-names>T</given-names></name><name><surname>Ishitsuka</surname><given-names>H</given-names></name></person-group><article-title>Induction of thymidine phosphrylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts</article-title><source>Clin Cancer Res</source><year>1998</year><volume>4</volume><fpage>1013</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">9563897</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franchi</surname><given-names>F</given-names></name><name><surname>Barone</surname><given-names>C</given-names></name><name><surname>Seminara</surname><given-names>P</given-names></name><name><surname>Codacci-Pisanelli</surname><given-names>G</given-names></name><name><surname>Codacci-Pisanelli</surname><given-names>M</given-names></name><name><surname>Ferri</surname><given-names>GM</given-names></name><name><surname>Garufi</surname><given-names>C</given-names></name><name><surname>Grieco</surname><given-names>A</given-names></name><name><surname>Pagani</surname><given-names>V</given-names></name></person-group><article-title>5-Fluorouracil (FU) and mitomycin C(MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures</article-title><source>Med Oncol Tumor Pharmacother</source><year>1991</year><volume>8</volume><fpage>75</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">1749303</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>G</given-names></name><name><surname>O’Rourke</surname><given-names>K</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Gentz</surname><given-names>R</given-names></name><name><surname>Ebner</surname><given-names>R</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><article-title>The receptor for the cytotoxic ligand TRAIL</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>111</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1126/science.276.5309.111</pub-id><pub-id pub-id-type="pmid">9082980</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>G</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>YF</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Gentz</surname><given-names>R</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><article-title>An antagonist decoy receptor and a death domain-containing receptor for TRAIL</article-title><source>Science</source><year>1997</year><volume>277</volume><fpage>815</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1126/science.277.5327.815</pub-id><pub-id pub-id-type="pmid">9242610</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Thome</surname><given-names>M</given-names></name><name><surname>Burns</surname><given-names>K</given-names></name><name><surname>Bodmer</surname><given-names>JL</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name><name><surname>Holler</surname><given-names>N</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><article-title>TRAIL receptors 1 DR4 and 2 DR5 signal FADD-dependent apoptosis and activate NFkappaB</article-title><source>Immunity</source><year>1997</year><volume>7</volume><fpage>831</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80401-X</pub-id><pub-id pub-id-type="pmid">9430228</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>PM</given-names></name><name><surname>Eby</surname><given-names>M</given-names></name><name><surname>Jasmin</surname><given-names>A</given-names></name><name><surname>Bookwalter</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>J</given-names></name><name><surname>Hood</surname><given-names>L</given-names></name></person-group><article-title>Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway</article-title><source>Immunity</source><year>1997</year><volume>7</volume><fpage>821</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80400-8</pub-id><pub-id pub-id-type="pmid">9430227</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walczak</surname><given-names>H</given-names></name><name><surname>Degli-Esposti</surname><given-names>MA</given-names></name><name><surname>Johnson</surname><given-names>RS</given-names></name><name><surname>Smolak</surname><given-names>PJ</given-names></name><name><surname>Waugh</surname><given-names>JY</given-names></name><name><surname>Boiani</surname><given-names>N</given-names></name><name><surname>Timour</surname><given-names>MS</given-names></name><name><surname>Gerhart</surname><given-names>MJ</given-names></name><name><surname>Schooley</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Goodwin</surname><given-names>RG</given-names></name><name><surname>Rauch</surname><given-names>CT</given-names></name></person-group><article-title>TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL</article-title><source>EMBO J</source><year>1997</year><volume>16</volume><fpage>5386</fpage><lpage>5397</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.17.5386</pub-id><pub-id pub-id-type="pmid">9311998</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>GS</given-names></name><name><surname>Burns</surname><given-names>TF</given-names></name><name><surname>McDonald</surname><given-names>ER</given-names><suffix>3rd</suffix></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Meng</surname><given-names>R</given-names></name><name><surname>Krantz</surname><given-names>ID</given-names></name><name><surname>Kao</surname><given-names>G</given-names></name><name><surname>Gan</surname><given-names>DD</given-names></name><name><surname>Zhou</surname><given-names>JY</given-names></name><name><surname>Muschel</surname><given-names>R</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Spinner</surname><given-names>NB</given-names></name><name><surname>Markowitz</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>el-Deiry</surname><given-names>WS</given-names></name></person-group><article-title>KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene</article-title><source>Nat Genet</source><year>1997</year><volume>17</volume><fpage>141</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/ng1097-141</pub-id><pub-id pub-id-type="pmid">9326928</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>SR</given-names></name><name><surname>Schooley</surname><given-names>K</given-names></name><name><surname>Smolak</surname><given-names>PJ</given-names></name><name><surname>Din</surname><given-names>WS</given-names></name><name><surname>Huang</surname><given-names>CP</given-names></name><name><surname>Nicholl</surname><given-names>JK</given-names></name><name><surname>Sutherland</surname><given-names>GR</given-names></name><name><surname>Smith</surname><given-names>TD</given-names></name><name><surname>Rauch</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Goodwin</surname><given-names>RG</given-names></name></person-group><article-title>Identification and characterization of a new member of the TNF family that induces apoptosis</article-title><source>Immunity</source><year>1995</year><volume>3</volume><fpage>673</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/1074-7613(95)90057-8</pub-id><pub-id pub-id-type="pmid">8777713</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname><given-names>TS</given-names></name><name><surname>Lynch</surname><given-names>DH</given-names></name></person-group><article-title>TRAIL: a molecule with multiple receptors and control mechanisms</article-title><source>Curr Opin Immunol</source><year>1998</year><volume>10</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(98)80224-0</pub-id><pub-id pub-id-type="pmid">9794836</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacour</surname><given-names>S</given-names></name><name><surname>Hammann</surname><given-names>A</given-names></name><name><surname>Wotawa</surname><given-names>A</given-names></name><name><surname>Corcos</surname><given-names>L</given-names></name><name><surname>Solary</surname><given-names>E</given-names></name><name><surname>Dimanche-Boitrel</surname><given-names>MT</given-names></name></person-group><article-title>Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase activation and apoptosis</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>1645</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">11245478</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keane</surname><given-names>MM</given-names></name><name><surname>Ettenberg</surname><given-names>SA</given-names></name><name><surname>Nau</surname><given-names>MM</given-names></name><name><surname>Russell</surname><given-names>EK</given-names></name><name><surname>Lipkowitz</surname><given-names>S</given-names></name></person-group><article-title>Chemotherapy augments TRAIL-induced apoptosis in breast cell lines</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>734</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">9973225</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagane</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>G</given-names></name><name><surname>Weddle</surname><given-names>JJ</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><name><surname>Huang</surname><given-names>HJ</given-names></name></person-group><article-title>Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>847</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">10706092</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>SB</given-names></name><name><surname>Oyer</surname><given-names>R</given-names></name><name><surname>Spalding</surname><given-names>AC</given-names></name><name><surname>Anderson</surname><given-names>SM</given-names></name><name><surname>Johnson</surname><given-names>GL</given-names></name></person-group><article-title>Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL</article-title><source>Mol Cell Biol</source><year>2000</year><volume>20</volume><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.1.205-212.2000</pub-id><pub-id pub-id-type="pmid">10594023</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>TR</given-names></name><name><surname>Shankar</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Asim</surname><given-names>M</given-names></name><name><surname>Srivastava</surname><given-names>RK</given-names></name></person-group><article-title>Synergistic interactions of chemotherapeutic drugs and tumor necrosis factorrelated apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>5390</fpage><lpage>5400</lpage><pub-id pub-id-type="pmid">14500373</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asakuma</surname><given-names>J</given-names></name><name><surname>Sumitomo</surname><given-names>M</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name></person-group><article-title>Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>1365</fpage><lpage>1370</lpage><pub-id pub-id-type="pmid">12649200</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuckey</surname><given-names>DW</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name></person-group><article-title>TRAIL on trial: preclinical advances in cancer therapy</article-title><source>Trends Mol Med</source><year>2013</year><volume>19</volume><fpage>685</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2013.08.007</pub-id><pub-id pub-id-type="pmid">24076237</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Hyperthermia enhances tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human cancer cells</article-title><source>Int J Hyperthermia</source><year>2006</year><volume>22</volume><fpage>713</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1080/02656730601074052</pub-id><pub-id pub-id-type="pmid">17391000</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells</article-title><source>J Cell Biochem</source><year>2008</year><volume>103</volume><fpage>98</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1002/jcb.21389</pub-id><pub-id pub-id-type="pmid">17520700</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Basse</surname><given-names>P</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>BC</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Hyperthermia-enhanced TRAIL—and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells</article-title><source>J Cell Biochem</source><year>2012</year><volume>113</volume><fpage>1547</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1002/jcb.24243</pub-id><pub-id pub-id-type="pmid">22174016</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer</article-title><source>Mol Cancer Res</source><year>2012</year><volume>10</volume><fpage>1567</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-12-0209-T</pub-id><pub-id pub-id-type="pmid">23051936</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewey</surname><given-names>WC</given-names></name><name><surname>Sapareto</surname><given-names>SA</given-names></name><name><surname>Betten</surname><given-names>DA</given-names></name></person-group><article-title>Hyperthermic radiosensitization of synchronous Chinese hamster cells: relationship between lethality and chromosomal aberrations</article-title><source>Radiat Res</source><year>1978</year><volume>76</volume><fpage>48</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.2307/3574926</pub-id><pub-id pub-id-type="pmid">569879</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holahan</surname><given-names>EV</given-names></name><name><surname>Highfield</surname><given-names>DP</given-names></name><name><surname>Holahan</surname><given-names>PK</given-names></name><name><surname>Dewey</surname><given-names>WC</given-names></name></person-group><article-title>Hyperthermic killing and hyperthermic radiosensitization in Chinese hamster ovary cells: effects of pH and thermal tolerance</article-title><source>Radiat Res</source><year>1984</year><volume>97</volume><fpage>108</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.2307/3576193</pub-id><pub-id pub-id-type="pmid">6695037</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampinga</surname><given-names>HH</given-names></name><name><surname>Dikomey</surname><given-names>E</given-names></name></person-group><article-title>Hyperthermic radiosensitization: mode of action and clinical relevance</article-title><source>Int J Radiat Biol</source><year>2001</year><volume>77</volume><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1080/09553000010024687</pub-id><pub-id pub-id-type="pmid">11304434</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>GP</given-names></name><name><surname>Klugo</surname><given-names>RC</given-names></name><name><surname>Hetzel</surname><given-names>FW</given-names></name><name><surname>Barton</surname><given-names>EE</given-names></name><name><surname>Cerny</surname><given-names>JC</given-names></name></person-group><article-title>The synergistic effect of hyperthermia and chemotherapy on murine transitional cell carcinoma</article-title><source>J Urol</source><year>1984</year><volume>132</volume><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">6540817</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>TS</given-names></name><name><surname>Sweets</surname><given-names>CC</given-names></name><name><surname>White</surname><given-names>DM</given-names></name><name><surname>Gerner</surname><given-names>EW</given-names></name></person-group><article-title>Effect of heating on lethality due to hyperthermia and selected chemotherapeutic drugs</article-title><source>J Natl Cancer Inst</source><year>1982</year><volume>68</volume><fpage>487</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">6950177</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>SH</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Yoshimoto</surname><given-names>Y</given-names></name><name><surname>Yoo</surname><given-names>JS</given-names></name><name><surname>Abdel-Wahab</surname><given-names>OI</given-names></name><name><surname>Abdel-Wahab</surname><given-names>Z</given-names></name><name><surname>Chu</surname><given-names>E</given-names></name><name><surname>Pruitt</surname><given-names>SK</given-names></name><name><surname>Friedman</surname><given-names>HS</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name><name><surname>Tyler</surname><given-names>DS</given-names></name></person-group><article-title>Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>289</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0210</pub-id><pub-id pub-id-type="pmid">16397054</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Lagasse</surname><given-names>E</given-names></name><name><surname>Kwon</surname><given-names>YT</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells</article-title><source>Cell Death Dis</source><year>2013</year><volume>4</volume><fpage>e577</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.104</pub-id><pub-id pub-id-type="pmid">23559011</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>I</given-names></name><name><surname>Baumann</surname><given-names>S</given-names></name><name><surname>Krammer</surname><given-names>PH</given-names></name><name><surname>Kirchhoff</surname><given-names>S</given-names></name></person-group><article-title>Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>20633</fpage><lpage>20640</lpage><pub-id pub-id-type="doi">10.1074/jbc.M101780200</pub-id><pub-id pub-id-type="pmid">11279218</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kober</surname><given-names>AM</given-names></name><name><surname>Legewie</surname><given-names>S</given-names></name><name><surname>Pforr</surname><given-names>C</given-names></name><name><surname>Fricker</surname><given-names>N</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Krammer</surname><given-names>PH</given-names></name><name><surname>Lavrik</surname><given-names>IN</given-names></name></person-group><article-title>Caspase-8 activity has an essential role in CD95/Fas-mediated MAPK activation</article-title><source>Cell Death Dis</source><year>2011</year><volume>2</volume><fpage>e212</fpage><pub-id pub-id-type="doi">10.1038/cddis.2011.93</pub-id><pub-id pub-id-type="pmid">21975294</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrish</surname><given-names>AB</given-names></name><name><surname>Freel</surname><given-names>CD</given-names></name><name><surname>Kornbluth</surname><given-names>S</given-names></name></person-group><article-title>Cellular mechanisms controlling caspase activation and function</article-title><source>Cold Spring Harb Perspect Biol</source><year>2013</year><volume>5</volume><fpage>a008672</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a008672</pub-id><pub-id pub-id-type="pmid">23732469</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiaofeng</surname><given-names>W</given-names></name><name><surname>Yukai</surname><given-names>H</given-names></name><name><surname>Louis</surname><given-names>DF</given-names></name><name><surname>Kam</surname><given-names>MH</given-names></name><name><surname>Leaf</surname><given-names>H</given-names></name></person-group><article-title>Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex TRAIL fusion protein</article-title><source>Mol Ther</source><year>2001</year><volume>3</volume><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1006/mthe.2001.0280</pub-id><pub-id pub-id-type="pmid">11273779</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Tung</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Breakefield</surname><given-names>XO</given-names></name></person-group><article-title>Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>3236</fpage><lpage>3242</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3516</pub-id><pub-id pub-id-type="pmid">15126365</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>S</given-names></name><name><surname>Kitamura</surname><given-names>M</given-names></name><name><surname>Harris-Stansil</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>U</given-names></name><name><surname>Phipps</surname><given-names>ML</given-names></name></person-group><article-title>Construction of adenovirus vectors through Cre-lox recombination</article-title><source>J Virol</source><year>1997</year><volume>71</volume><fpage>1842</fpage><lpage>1849</lpage><pub-id pub-id-type="pmid">9032314</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bartlett</surname><given-names>DL</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death</article-title><source>Biochem Pharmacol</source><year>2014</year><volume>88</volume><fpage>178</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2014.01.027</pub-id><pub-id pub-id-type="pmid">24486574</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirawan</surname><given-names>E</given-names></name><name><surname>Vande Walle</surname><given-names>L</given-names></name><name><surname>Kersse</surname><given-names>K</given-names></name><name><surname>Cornelis</surname><given-names>S</given-names></name><name><surname>Claerhout</surname><given-names>S</given-names></name><name><surname>Vanoverberghe</surname><given-names>I</given-names></name><name><surname>Roelandt</surname><given-names>R</given-names></name><name><surname>De Rycke</surname><given-names>R</given-names></name><name><surname>Verspurten</surname><given-names>J</given-names></name><name><surname>Declercq</surname><given-names>W</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name><name><surname>Vanden Berghe</surname><given-names>T</given-names></name><name><surname>Lippens</surname><given-names>S</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name></person-group><article-title>Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria</article-title><source>Cell Death Dis</source><year>2010</year><volume>1</volume><fpage>e18</fpage><pub-id pub-id-type="doi">10.1038/cddis.2009.16</pub-id><pub-id pub-id-type="pmid">21364619</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>WX</given-names></name><name><surname>Yin</surname><given-names>XM</given-names></name><name><surname>Sobol</surname><given-names>RW</given-names></name><name><surname>Stolz</surname><given-names>DB</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>3625</fpage><lpage>3634</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4475</pub-id><pub-id pub-id-type="pmid">21444671</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itakura</surname><given-names>E</given-names></name><name><surname>Kishi</surname><given-names>C</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Mizushima</surname><given-names>N</given-names></name></person-group><article-title>Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG</article-title><source>Mol Biol Cell</source><year>2008</year><volume>19</volume><fpage>5360</fpage><lpage>5372</lpage><pub-id pub-id-type="doi">10.1091/mbc.E08-01-0080</pub-id><pub-id pub-id-type="pmid">18843052</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iijima</surname><given-names>K</given-names></name><name><surname>Ohara</surname><given-names>M</given-names></name><name><surname>Seki</surname><given-names>R</given-names></name><name><surname>Tauchi</surname><given-names>H</given-names></name></person-group><article-title>Dancing on damaged chromatin: functions of ATM and the RAD50/MRE11/NBS1 complex in cellular responses to DNA damage</article-title><source>J Radiat Res</source><year>2008</year><volume>49</volume><fpage>451</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1269/jrr.08065</pub-id><pub-id pub-id-type="pmid">18772547</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Shamma</surname><given-names>A</given-names></name><name><surname>Morimura</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>C</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name></person-group><article-title>Regulatory interaction between NBS1 and DNMT1 responding to DNA damage</article-title><source>J Biochem</source><year>2013</year><volume>154</volume><fpage>429</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1093/jb/mvt071</pub-id><pub-id pub-id-type="pmid">23918933</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharbanda</surname><given-names>S</given-names></name><name><surname>Ren</surname><given-names>R</given-names></name><name><surname>Pandey</surname><given-names>P</given-names></name><name><surname>Shafman</surname><given-names>TD</given-names></name><name><surname>Feller</surname><given-names>SM</given-names></name><name><surname>Weichselbaum</surname><given-names>RR</given-names></name><name><surname>Kufe</surname><given-names>DW</given-names></name></person-group><article-title>Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>785</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/376785a0</pub-id><pub-id pub-id-type="pmid">7651539</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>BD</given-names></name><name><surname>Hughes-Davies</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name></person-group><article-title>Cdk2 kinase phosphorylates serine 315 of human p53 in vitro</article-title><source>Oncogene</source><year>1995</year><volume>11</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">7624134</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>DM</given-names></name><name><surname>Palmer</surname><given-names>RH</given-names></name><name><surname>Campbell</surname><given-names>DG</given-names></name><name><surname>Meek</surname><given-names>DW</given-names></name></person-group><article-title>Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme</article-title><source>Oncogene</source><year>1992</year><volume>7</volume><fpage>1361</fpage><lpage>1369</lpage><pub-id pub-id-type="pmid">1620549</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>SR</given-names></name><name><surname>Campbell</surname><given-names>LE</given-names></name><name><surname>Meek</surname><given-names>DW</given-names></name></person-group><article-title>Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation</article-title><source>Nucleic Acids Res</source><year>1996</year><volume>24</volume><fpage>1119</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1093/nar/24.6.1119</pub-id><pub-id pub-id-type="pmid">8604347</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudier</surname><given-names>J</given-names></name><name><surname>Delphin</surname><given-names>C</given-names></name><name><surname>Grunwald</surname><given-names>D</given-names></name><name><surname>Khochbin</surname><given-names>S</given-names></name><name><surname>Lawrence</surname><given-names>JJ</given-names></name></person-group><article-title>Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein</article-title><source>Proc Natl Acad Sci USA</source><year>1992</year><volume>89</volume><fpage>11627</fpage><lpage>11631</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.23.11627</pub-id><pub-id pub-id-type="pmid">1454855</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>DM</given-names></name><name><surname>Campbell</surname><given-names>DG</given-names></name><name><surname>Caudwell</surname><given-names>FB</given-names></name><name><surname>Meek</surname><given-names>DW</given-names></name></person-group><article-title>Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>9253</fpage><lpage>9260</lpage><pub-id pub-id-type="pmid">7510706</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>DM</given-names></name><name><surname>Campbell</surname><given-names>LE</given-names></name><name><surname>Campbell</surname><given-names>DG</given-names></name><name><surname>Meek</surname><given-names>DW</given-names></name></person-group><article-title>p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>5511</fpage><lpage>5518</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.10.5511</pub-id><pub-id pub-id-type="pmid">7890669</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamal</surname><given-names>S</given-names></name><name><surname>Ziff</surname><given-names>EB</given-names></name></person-group><article-title>Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo</article-title><source>Oncogene</source><year>1995</year><volume>10</volume><fpage>2095</fpage><lpage>2101</lpage><pub-id pub-id-type="pmid">7784054</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shieh</surname><given-names>SY</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Taya</surname><given-names>Y</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><article-title>DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2</article-title><source>Cell</source><year>1997</year><volume>91</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80416-X</pub-id><pub-id pub-id-type="pmid">9363941</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibbetts</surname><given-names>RS</given-names></name><name><surname>Brumbaugh</surname><given-names>KM</given-names></name><name><surname>Williams</surname><given-names>JM</given-names></name><name><surname>Sarkaria</surname><given-names>JN</given-names></name><name><surname>Cliby</surname><given-names>WA</given-names></name><name><surname>Shieh</surname><given-names>SY</given-names></name><name><surname>Taya</surname><given-names>Y</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name><name><surname>Abraham</surname><given-names>RT</given-names></name></person-group><article-title>A role for ATR in the DNA damage-induced phosphorylation of p53</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1101/gad.13.2.152</pub-id><pub-id pub-id-type="pmid">9925639</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcala</surname><given-names>MA</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Yoo</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>BC</given-names></name><name><surname>Bartlett</surname><given-names>DL</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors</article-title><source>J Cell Biochem</source><year>2010</year><volume>110</volume><fpage>1073</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1002/jcb.22619</pub-id><pub-id pub-id-type="pmid">20544795</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>BK</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Nguyen</surname><given-names>HN</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Song</surname><given-names>JJ</given-names></name></person-group><article-title>MEKK1/MEKK4 are responsible for TRAIL-induced JNK/p38 phosphorylation</article-title><source>Oncol Rep</source><year>2011</year><volume>25</volume><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">21152872</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e73654</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0073654</pub-id><pub-id pub-id-type="pmid">24013390</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ubersax</surname><given-names>JA</given-names></name><name><surname>Ferrell</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>Mechanisms of specificity in protein phosphorylation</article-title><source>Nat Rev Mol Cell Biol</source><year>2007</year><volume>8</volume><fpage>530</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/nrm2203</pub-id><pub-id pub-id-type="pmid">17585314</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Haldar</surname><given-names>S</given-names></name></person-group><article-title>Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis</article-title><source>FEBS Lett</source><year>2003</year><volume>538</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(03)00131-5</pub-id><pub-id pub-id-type="pmid">12633850</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharbanda</surname><given-names>S</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Pandey</surname><given-names>P</given-names></name><name><surname>Kaneki</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>YN</given-names></name><name><surname>Campbell</surname><given-names>A</given-names></name><name><surname>Sudha</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>ZM</given-names></name><name><surname>Narula</surname><given-names>J</given-names></name><name><surname>Weichselbaum</surname><given-names>R</given-names></name><name><surname>Nalin</surname><given-names>C</given-names></name><name><surname>Kufe</surname><given-names>D</given-names></name></person-group><article-title>Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>322</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.1.322</pub-id><pub-id pub-id-type="pmid">10617621</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Pattingre</surname><given-names>S</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Bassik</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name></person-group><article-title>JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy</article-title><source>Mol Cell</source><year>2008</year><volume>30</volume><fpage>678</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.06.001</pub-id><pub-id pub-id-type="pmid">18570871</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000434 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000434 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:4196052
|texte= Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:25156145" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |